Biosimulation Market - Global Forecast to 2029
商品番号 : SMB-69243
| 出版社 | MarketsandMarkets |
| 出版年月 | 2024年10月 |
| ページ数 | 378 |
| 図表数 | 515 |
| 価格タイプ | シングルユーザライセンス |
| 価格 | USD 4,950 |
| 種別 | 英文調査報告書 |
Report Overview
The biosimulation market is projected to reach USD 9.18 billion by 2029 from USD 4.24 billion in 2024, at a CAGR of 16.7% from 2024 to 2029.
バイオシミュレーション市場は、2024 年から 2029 年まで 16.7% の CAGR で成長し、2024 年の 42 億 4000 万米ドルから 2029 年までに 91 億 8000 万米ドルに達すると予測されています。
Increasing need for cost and time reduction in the drug development process has been one of the major drivers in the adoption of biosimulation tools. These tools predict how the drugs will behave inside the human body, potentially minimizing the requirements of extensive clinical trials. But there are some restraining factors in the market; the cost of biosimulation technologies is discouragingly high and thus, prohibitive to small companies and the academic community.
“Drug Discovery held the largest market share in the biosimulation market in 2023, by application.”
The biosimulation market is segmented based on application into drug discovery, drug development, disease modelling, manufacturing & supply chain management and other applications. The drug discovery segment held the largest market share in 2023, since it plays a vital role in accelerating and enriching early stages of pharmaceutical research. The tool created by biosimulation makes it possible for the researchers to simulate drug behavior at the molecular level, predict biological target interaction, even identify potential drug candidates before they reach the costly phases of preclinical and clinical trial stages. It reduces both the time and the cost incurred during the process of drug development.
“By deployment model, the cloud-based model segment is expected to register the fastest growth over the forecast period.”
By deployment model, the biosimulation market is divided into on-premises, cloud-based and hybrid model. The cloud-based segment is projected to be the fastest-growing segment over the forecast period. Cloud-based platforms are much more flexible and scalable and make very significant computational resources available at the point when they are needed to run complex biosimulations. This flexibility makes cloud models highly cost-effective, particularly for smaller biotech firms and academic institutions that would lack the infrastructure for high-performance computing.
“Asia Pacific is estimated to register the highest CAGR over the forecast period.”
The biosimulation market is geographically segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. The Asia Pacific biosimulation market is projected to register highest CAGR during the forecast period. The growth of this region is due to an aggressive build-out of the pharmaceutical and biotechnology industry in this region, especially in China, India, and South Korea, where large investments are committed to drug discovery and development. Markets in this region increasingly embrace sophisticated technology, such as biosimulation, to rationalize their R&D processes, reduce costs, and accelerate their time-to-market for new drugs.
Breakdown of supply-side primary interviews by company type, designation, and region:
- By Company Type: Tier 1 (40%), Tier 2 (35%), and Tier 3 (25%)
- By Designation: Managers (40%), Directors (35%), and Others (25%)
- By Region: North America (40%), Europe (30%), Asia Pacific (20%), Latin America (5%) and Middle East Africa (5%)
List of Companies Profiled in the Report:
o Certara USA. (US)
o Simulations Plus. (US)
o Dassault Systèmes (France)
o Schrödinger, Inc. (US)
o Advanced Chemistry Development, Inc. (Canada)
o Chemical Computing Group ULC. (Canada)
o Rosa & Co. LLC. (US)
o Genedata AG (US)
o Physiomics Plc (United Kingdom)
o In Silico Biosciences. (US)
o Allucent. (US)
o OpenEye, Cadence Molecular Sciences. (US)
o Cellworks Group, Inc. (US)
o VeriSIM Life. (US)
o Netabolics SRL (Italy)
o Charnwood Discovery (United Kingdom)
o The MathWorks, Inc. (US)
o ANSYS, Inc (US)
o Instem Group of Companies (United Kingdom)
o Insilico Medicine (US)
o SCM – Software Chemistry & Materials (Netherlands)
o BioSymetrics, Inc. (Canada)
o Atomwise Inc. (US)
o insitro. US)
o Clinithink. (US)
Research Coverage:
This research report categorizes the biosimulation market by offerings (software and services), application (drug discovery, drug development, disease modelling, manufacturing & supply chain and other applications), therapeutic area (oncology, cardiovascular disease, neurological disorders, infectious disease, and others), revenue model (license-based model, subscription-based model, service-based model, and pay-per-use model), deployment model (on-premises model, cloud-based model, and hybrid model) end user (pharmaceutical & biotechnology companies, contract research organizations (CROs), academic & research institutions, regulatory bodies and others), and region. The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, challenges, and opportunities, influencing the growth of the biosimulation market. A thorough analysis of the key industry players has been done to provide insights into their business overview, offerings, and key strategies such as acquisitions, collaborations, partnerships, mergers, product/service launches & enhancements, and approvals in the biosimulation market. Competitive analysis of upcoming startups in the biosimulation market ecosystem is covered in this report.
Reasons to Buy the Report
The report will help market leaders/new entrants in this market with information on the closest approximations of the revenue numbers for the overall biosimulation market and the subsegments. This report will help stakeholders understand the competitive landscape and gain more insights to better position their businesses and plan suitable go-to-market strategies. The report also helps stakeholders understand the market pulse and provides information on key market drivers, restraints, challenges, and opportunities.
The report provides insights on the following pointers:
- Analysis of key drivers: (increase in R&D investments in the pharmaceutical and biotechnology industries), restraints (lack of standardization), opportunities (use of biosimulation solution for pediatric drug development), and challenges (difficulty in matching the complexity of biological systems and processes) influencing the growth of the biosimulation market.
- Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities, and new product & service launches in the biosimulation market.
- Market Development: Comprehensive information about lucrative markets – the report analyses the biosimulation market across varied regions.
- Market Diversification: Exhaustive information about new products & services, untapped geographies, recent developments, and investments in the biosimulation market.
- Competitive Assessment: In-depth assessment of market shares, growth strategies, and service offerings of leading players such as Certara USA. (US), Simulations Plus. (US), Dassault Systèmes (France), Schrödinger, Inc. (US), Advanced Chemistry Development, Inc. (Canada), Chemical Computing Group ULC. (Canada), Rosa & Co. LLC. (US), Genedata AG (US), etc. among others in biosimulation market.
Table of Contents
1 INTRODUCTION 35
1.1 STUDY OBJECTIVES 35
1.2 MARKET DEFINITION 35
1.3 STUDY SCOPE 36
1.3.1 MARKETS COVERED & REGIONAL SCOPE 36
1.3.2 INCLUSIONS & EXCLUSIONS 37
1.3.3 YEARS CONSIDERED 38
1.4 CURRENCY CONSIDERED 39
1.5 STAKEHOLDERS 39
1.6 SUMMARY OF CHANGES 39
2 RESEARCH METHODOLOGY 41
2.1 RESEARCH DATA 41
2.1.1 SECONDARY DATA 42
2.1.1.1 Key data from secondary sources 43
2.1.2 PRIMARY DATA 43
2.1.2.1 Key data from primary sources 45
2.1.2.2 Insights from primary experts 46
2.2 MARKET SIZE ESTIMATION 47
2.3 DATA TRIANGULATION 51
2.4 MARKET SHARE ESTIMATION 52
2.5 RESEARCH ASSUMPTIONS 52
2.6 LIMITATIONS 52
2.6.1 METHODOLOGY-RELATED LIMITATIONS 52
2.6.2 SCOPE-RELATED LIMITATIONS 53
2.7 RISK ASSESSMENT 53
3 EXECUTIVE SUMMARY 54
4 PREMIUM INSIGHTS 60
4.1 BIOSIMULATION MARKET OVERVIEW 60
4.2 ASIA PACIFIC: BIOSIMULATION MARKET, BY REVENUE MODEL AND COUNTRY (2023) 61
4.3 BIOSIMULATION MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 62
4.4 BIOSIMULATION MARKET: REGIONAL MIX (2024−2029) 62
4.5 BIOSIMULATION MARKET: DEVELOPED VS. EMERGING ECONOMIES 63
5 MARKET OVERVIEW 64
5.1 INTRODUCTION 64
5.2 MARKET DYNAMICS 64
5.2.1 DRIVERS 65
5.2.1.1 Increasing R&D investments in pharmaceutical and biotechnology industries 65
5.2.1.2 Growing adoption of biosimulation software by regulatory bodies 65
5.2.1.3 Integration of technologically advanced Quantitative Systems Pharmacology (QSP) 65
5.2.1.4 Need to curtail drug discovery and development costs 66
5.2.1.5 Growth in biologics and biosimilars markets 66
5.2.2 RESTRAINTS 67
5.2.2.1 Lack of standardization 67
5.2.2.2 Data availability and quality 67
5.2.3 OPPORTUNITIES 67
5.2.3.1 Emerging applications 67
5.2.3.2 Use of biosimulation solutions for pediatric drug development 68
5.2.4 CHALLENGES 68
5.2.4.1 Difficulties in matching complexity of biological systems and processes 68
5.2.4.2 Shortage of biosimulation and modeling experts 69
5.3 ECOSYSTEM ANALYSIS 69
5.3.1 SOFTWARE PROVIDERS 69
5.3.2 PHARMACEUTICAL & BIOTECH COMPANIES 69
5.3.3 CONTRACT RESEARCH ORGANIZATIONS (CROS) 69
5.3.4 REGULATORY BODIES 69
5.3.5 ACADEMIC & RESEARCH INSTITUTIONS 69
5.4 CASE STUDY ANALYSIS 71
5.4.1 CASE STUDY 1: OPTIMIZING ASCIMINIB DEVELOPMENT THROUGH ADVANCED PBPK MODELING 71
5.4.2 CASE STUDY 2: COMPUTATIONAL DISCOVERY OF SELECTIVE WEE1 INHIBITORS FOR CANCER 71
5.4.3 CASE STUDY 3: EFFICIENT CLINICAL TRIAL UTILIZING SCALE MANAGEMENT EXPERTISE 72
5.5 VALUE CHAIN ANALYSIS 72
5.6 PORTER’S FIVE FORCES ANALYSIS 74
5.6.1 BARGAINING POWER OF SUPPLIERS 75
5.6.2 BARGAINING POWER OF BUYERS 75
5.6.3 THREAT OF SUBSTITUTES 75
5.6.4 THREAT OF NEW ENTRANTS 75
5.6.5 INTENSITY OF COMPETITIVE RIVALRY 75
5.7 REGULATORY ANALYSIS 76
5.7.1 REGULATORY LANDSCAPE 76
5.7.1.1 North America 76
5.7.1.2 Europe 77
5.7.1.3 Asia Pacific 77
5.7.1.4 Latin America 78
5.7.1.5 Middle East & Africa 78
5.7.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 78
5.8 PATENT ANALYSIS 81
5.8.1 PATENT PUBLICATION TRENDS FOR BIOSIMULATION 81
5.8.2 JURISDICTION AND TOP APPLICANT ANALYSIS 81
5.9 TECHNOLOGY ANALYSIS 82
5.9.1 KEY TECHNOLOGIES 82
5.9.1.1 Mathematical modeling 82
5.9.1.2 Software platforms 83
5.9.1.3 Quantitative systems pharmacology (QSP) 83
5.9.2 COMPLEMENTARY TECHNOLOGIES 83
5.9.2.1 Data analytics 83
5.9.2.2 Machine learning and AI 83
5.9.3 ADJACENT TECHNOLOGIES 83
5.9.3.1 In silico trials 83
5.10 INDUSTRY TRENDS 84
5.10.1 DISCOVERY OF BIOMARKERS 84
5.10.2 ADOPTION IN PERSONALIZED MEDICINE 84
5.11 PRICING ANALYSIS 84
5.11.1 INDICATIVE PRICING ANALYSIS OF KEY PLAYERS, BY OFFERING, 2023 85
5.11.2 AVERAGE SELLING PRICE TREND, BY REGION (QUALITATIVE) 85
5.12 KEY CONFERENCES & EVENTS, 2024–2025 86
5.13 KEY STAKEHOLDERS & BUYING CRITERIA 86
5.13.1 BUYING CRITERIA 87
5.14 TRENDS & DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 88
5.15 END-USER ANALYSIS 88
5.15.1 UNMET NEEDS 88
5.15.2 END-USER EXPECTATIONS 89
5.16 INVESTMENT & FUNDING SCENARIO 90
5.17 IMPACT OF AI/GEN AI ON BIOSIMULATION MARKET 90
5.17.1 KEY USE CASES 91
5.17.2 IMPACT OF AI/GEN AI ON INTERCONNECTED AND ADJACENT ECOSYSTEMS 92
5.17.2.1 Case study 92
5.17.2.2 Bioinformatics market 93
5.17.2.3 Drug discovery services market 93
5.17.2.4 Drug discovery informatics market 93
5.17.3 USER READINESS & IMPACT ASSESSMENT 93
5.17.3.1 User readiness 93
5.17.3.1.1 Pharmaceutical & biotechnology companies 93
5.17.3.1.2 Contract research organizations 94
5.17.3.2 Impact assessment 94
5.17.3.2.1 User A: Pharmaceutical & biotechnology companies 94
5.17.3.2.1.1 Implementation 94
5.17.3.2.1.2 Impact 94
5.17.3.2.2 User B: Academic & research institutes 95
5.17.3.2.2.1 Implementation 95
5.17.3.2.2.2 Impact 95
6 BIOSIMULATION MARKET, BY OFFERING 96
6.1 INTRODUCTION 97
6.2 SOFTWARE 97
6.2.1 STANDALONE MODULES 98
6.2.1.1 Molecular modeling & simulation software 100
6.2.1.1.1 Growing importance of molecular modeling & simulation in drug discovery and development to accelerate market growth 100
6.2.1.2 PK/PD modeling & simulation software 101
6.2.1.2.1 Pivotal role in early drug development phase to boost market growth 101
6.2.1.3 PBPK modeling & simulation software 102
6.2.1.3.1 Widespread use by regulatory bodies to drive PBPK modeling & simulation software market 102
6.2.1.4 Toxicity prediction software 103
6.2.1.4.1 Pressing need for toxicity prediction in drug discovery and development is driving the market 103
6.2.1.5 Clinical trial simulation software 104
6.2.1.5.1 High failure rate of clinical trials to accelerate growth 104
6.2.1.6 Other biosimulation software 105
6.2.2 INTEGRATED SOFTWARE SUITES/PLATFORMS 106
6.2.2.1 Need for efficient R&D tools to accelerate growth of integrated platforms 106
6.3 SERVICES 107
6.3.1 CONSULTING & ADVISORY 109
6.3.1.1 Need to focus on core competencies to drive need for consulting & advisory services 109
6.3.2 IMPLEMENTATION, TRAINING, AND SUPPORT 110
6.3.2.1 Need for well-trained professionals and experts to accelerate market growth 110
6.3.3 DATA ANALYSIS & INTERPRETATION 111
6.3.3.1 Accurate and precise interpretation of data to drive need for data analysis & interpretation services 111
7 BIOSIMULATION MARKET, BY APPLICATION 112
7.1 INTRODUCTION 113
7.2 DRUG DISCOVERY 113
7.2.1 TARGET IDENTIFICATION & VALIDATION 115
7.2.1.1 Need for identification of optimal targets in drug discovery to drive market 115
7.2.2 LEAD IDENTIFICATION & OPTIMIZATION 116
7.2.2.1 Crucial role in facilitating viable drug discovery to accelerate market growth 116
7.3 DRUG DEVELOPMENT 117
7.3.1 PRECLINICAL TESTING 118
7.3.1.1 PK/PD 120
7.3.1.1.1 Critical role of PK/PD studies in drug development to drive market 120
7.3.1.2 ADME/Toxicology 121
7.3.1.2.1 Growing role in selection of potent drug molecules to boost market growth 121
7.3.2 CLINICAL TRIALS 122
7.3.2.1 Phase I 123
7.3.2.1.1 Growing need to ease decision-making process to drive segmental growth 123
7.3.2.2 Phase II 124
7.3.2.2.1 Efficiency in dose assessment and product efficacy to drive growth 124
7.3.2.3 Phase III 125
7.3.2.3.1 Need to curtail large costs involved in trials to propel demand 125
7.3.2.4 Phase IV/Post-marketing surveillance 126
7.3.2.4.1 Ability to assist researchers in process innovation and decision support to drive adoption 126
7.4 DISEASE MODELING 127
7.4.1 CAPABILITY TO PREDICT DISEASE DYNAMICS AND INFORM THERAPEUTIC STRATEGIES TO DRIVE MARKET GROWTH 127
7.5 MANUFACTURING & SUPPLY CHAIN MANAGEMENT 128
7.5.1 PRODUCTION PLANNING & OPTIMIZATION 130
7.5.1.1 Need for proper production planning and execution to drive market growth 130
7.5.2 QUALITY CONTROL & PROCESS MONITORING 131
7.5.2.1 Adherence to maintaining product quality to fuel market growth 131
7.5.3 DEMAND FORECASTING & INVENTORY MANAGEMENT 131
7.5.3.1 Need to forecast demand effectively to drive market growth 131
7.5.4 RISK MANAGEMENT & CONTINGENCY PLANNING 132
7.5.4.1 Need to maintain operational continuity to support market growth 132
7.5.5 OTHER MANUFACTURING & SUPPLY CHAIN MANAGEMENT APPLICATIONS 133
7.6 OTHER APPLICATIONS 134
8 BIOSIMULATION MARKET, BY THERAPEUTIC AREA 136
8.1 INTRODUCTION 137
8.2 ONCOLOGY 137
8.2.1 HIGH PREVALENCE OF CANCER AND SHORTAGE OF EFFECTIVE CANCER DRUGS TO DRIVE MARKET GROWTH 137
8.3 CARDIOVASCULAR DISEASES 138
8.3.1 RISING NEED FOR DRUGS TO TREAT CARDIOVASCULAR DISEASES TO BOOST MARKET 138
8.4 NEUROLOGICAL DISORDERS 139
8.4.1 NEED TO BOOST DRUG DISCOVERY AND DEVELOPMENT FOR NEUROLOGICAL DISORDERS TO SUPPORT MARKET GROWTH 139
8.5 INFECTIOUS DISEASES 140
8.5.1 RISING EPIDEMIC OUTBREAKS TO BOOST DRUG DISCOVERY ACTIVITY 140
8.6 OTHER THERAPEUTIC AREAS 141
9 BIOSIMULATION MARKET, BY REVENUE MODEL 143
9.1 INTRODUCTION 144
9.2 LICENSE-BASED MODELS 144
9.2.1 LICENSE-BASED MODELS TO ACCOUNT FOR LARGEST SHARE OF MARKET 144
9.3 SUBSCRIPTION-BASED MODELS 145
9.3.1 SUBSCRIPTION-BASED MODELS TO REGISTER HIGHEST GROWTH RATE DURING FORECAST PERIOD 145
9.4 SERVICE-BASED MODELS 146
9.4.1 SPECIALIZED SIMULATION EXPERTISE WITH SERVICE-BASED MODELS TO SUPPORT ADOPTION 146
9.5 PAY-PER-USE MODELS 147
9.5.1 RISING DEMAND FOR FLEXIBLE BIOSIMULATION SOLUTIONS WITHOUT UPFRONT COSTS TO SUPPORT MARKET GROWTH 147
10 BIOSIMULATION MARKET, BY DEPLOYMENT MODEL 149
10.1 INTRODUCTION 150
10.2 ON-PREMISE MODELS 150
10.2.1 OPTIMAL CONTROL ON DEPLOYMENT AND DATA BACKUP TO SUPPORT MARKET UPTAKE 150
10.3 CLOUD-BASED MODELS 151
10.3.1 CLOUD-BASED MODEL TO EXPERIENCE HIGHEST GROWTH RATE DURING FORECAST PERIOD 151
10.4 HYBRID MODELS 152
10.4.1 BALANCED CAPABILITIES OF HYBRID BIOSIMULATION MODELS TO ACCELERATE ADOPTION 152
11 BIOSIMULATION MARKET, BY END USER 154
11.1 INTRODUCTION 155
11.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES 155
11.2.1 INCREASING R&D EXPENDITURE FOR DRUG DISCOVERY AND DEVELOPMENT TO DRIVE MARKET 155
11.3 CONTRACT RESEARCH ORGANIZATIONS 156
11.3.1 RISING OUTSOURCING OF CLINICAL TRIAL ACTIVITIES TO CROS BY PHARMACEUTICAL COMPANIES TO DRIVE MARKET 156
11.4 ACADEMIC & RESEARCH INSTITUTES 157
11.4.1 FAVORABLE GOVERNMENT SUPPORT FOR RESEARCH TO SUPPORT MARKET GROWTH 157
11.5 REGULATORY BODIES 158
11.5.1 GROWING USAGE OF BIOSIMULATION SOFTWARE FOR CLINICAL TRIAL EFFICACY TO PROPEL MARKET GROWTH 158
11.6 OTHER END USERS 159
12 BIOSIMULATION MARKET, BY REGION 161
12.1 INTRODUCTION 162
12.2 NORTH AMERICA 162
12.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA 169
12.2.2 US 169
12.2.2.1 Rising government funding for pharmaceutical R&D to drive market 169
12.2.3 CANADA 175
12.2.3.1 Increasing funding by Canadian government in healthcare to drive market 175
12.3 EUROPE 181
12.3.1 MACROECONOMIC OUTLOOK FOR EUROPE 187
12.3.2 GERMANY 187
12.3.2.1 High number of sponsored clinical trials to drive uptake of biosimulation 187
12.3.3 UK 193
12.3.3.1 Investments by pharmaceutical sponsors for drug discovery services to boost market 193
12.3.4 FRANCE 198
12.3.4.1 Growing R&D pipeline for clinical trials to drive market 198
12.3.5 ITALY 204
12.3.5.1 Increasing government funds and favorable regulatory scenarios to fuel uptake 204
12.3.6 SPAIN 209
12.3.6.1 Established network of research centers to propel market 209
12.3.7 REST OF EUROPE 215
12.4 ASIA PACIFIC 220
12.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC 227
12.4.2 CHINA 227
12.4.2.1 Low cost of drug development and large pharmaceutical R&D base to drive market 227
12.4.3 INDIA 233
12.4.3.1 Growing pharmaceutical industry to fuel uptake of biosimulation 233
12.4.4 JAPAN 239
12.4.4.1 Established drug development infrastructure and biomedical research capabilities to support market growth 239
12.4.5 REST OF ASIA PACIFIC 244
12.5 LATIN AMERICA 249
12.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA 255
12.5.2 BRAZIL 255
12.5.2.1 Advancing biosimulation in region to support market growth 255
12.5.3 MEXICO 260
12.5.3.1 Government initiatives to enhance digital health to propel market growth 260
12.5.4 REST OF LATIN AMERICA 265
12.6 MIDDLE EAST & AFRICA 270
12.6.1 MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA 276
12.6.2 GCC COUNTRIES 276
12.6.2.1 Increase in healthcare investments to support market growth 276
12.6.3 REST OF MIDDLE EAST & AFRICA 282
13 COMPETITIVE LANDSCAPE 289
13.1 INTRODUCTION 289
13.2 KEY PLAYER STRATEGY/RIGHT TO WIN 289
13.2.1 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN BIOSIMULATION MARKET 290
13.3 REVENUE ANALYSIS, 2019–2023 291
13.4 MARKET SHARE ANALYSIS, 2023 291
13.4.1 CERTARA, USA (US) 293
13.4.2 DASSAULT SYSTÈMES (FRANCE) 293
13.4.3 SCHRÖDINGER, INC. (US) 293
13.4.4 SIMULATIONS PLUS (US) 293
13.4.5 ADVANCED CHEMISTRY DEVELOPMENT, INC. (CANADA) 294
13.5 RANKING OF KEY MARKET PLAYERS 294
13.6 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023 294
13.6.1 STARS 295
13.6.2 EMERGING LEADERS 295
13.6.3 PERVASIVE PLAYERS 295
13.6.4 PARTICIPANTS 295
13.6.5 COMPANY FOOTPRINT: KEY PLAYERS, 2023 297
13.6.5.1 Company footprint 297
13.6.5.2 Offering footprint 298
13.6.5.3 Application footprint 299
13.6.5.4 End-user footprint 300
13.6.5.5 Region footprint 301
13.7 COMPANY EVALUATION MATRIX: START-UP/SMES, 2023 302
13.7.1 PROGRESSIVE COMPANIES 302
13.7.2 RESPONSIVE COMPANIES 302
13.7.3 DYNAMIC COMPANIES 302
13.7.4 STARTING BLOCKS 302
13.7.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2023 304
13.8 COMPANY EVALUATION & FINANCIAL METRICS 306
13.9 BRAND/PRODUCT COMPARISON 307
13.10 COMPETITIVE SCENARIO 308
13.10.1 PRODUCT LAUNCHES & ENHANCEMENTS 308
13.10.2 DEALS 309
13.10.3 EXPANSIONS 310
13.10.4 OTHER DEVELOPMENTS 310
14 COMPANY PROFILES 311
14.1 KEY PLAYERS 311
14.1.1 CERTARA, USA 311
14.1.1.1 Business overview 311
14.1.1.2 Products & services offered 312
14.1.1.3 Recent developments 314
14.1.1.3.1 Product launches & enhancements 314
14.1.1.3.2 Deals 315
14.1.1.4 MnM view 316
14.1.1.4.1 Right to win 316
14.1.1.4.2 Strategic choices 316
14.1.1.4.3 Weaknesses & competitive threats 316
14.1.2 DASSAULT SYSTÈMES 317
14.1.2.1 Business overview 317
14.1.2.2 Products & services offered 318
14.1.2.3 Recent developments 319
14.1.2.3.1 Deals 319
14.1.2.4 MnM view 320
14.1.2.4.1 Right to win 320
14.1.2.4.2 Strategic choices 320
14.1.2.4.3 Weaknesses & competitive threats 320
14.1.3 SCHRÖDINGER, INC. 321
14.1.3.1 Business overview 321
14.1.3.2 Products & services offered 322
14.1.3.3 Recent developments 324
14.1.3.3.1 Deals 324
14.1.3.4 MnM view 325
14.1.3.4.1 Right to win 325
14.1.3.4.2 Strategic choices 325
14.1.3.4.3 Weaknesses & competitive threats 325
14.1.4 SIMULATIONS PLUS 326
14.1.4.1 Business overview 326
14.1.4.2 Products & services offered 327
14.1.4.3 Recent developments 331
14.1.4.3.1 Product launches & enhancements 331
14.1.4.3.2 Deals 332
14.1.4.3.3 Other developments 333
14.1.5 ADVANCED CHEMISTRY DEVELOPMENT, INC. 334
14.1.5.1 Business overview 334
14.1.5.2 Products & services offered 334
14.1.5.3 Recent developments 335
14.1.5.3.1 Product launches & enhancements 335
14.1.5.3.2 Deals 335
14.1.6 CHEMICAL COMPUTING GROUP ULC 336
14.1.6.1 Business overview 336
14.1.6.2 Products & services offered 336
14.1.6.3 Recent developments 337
14.1.6.3.1 Deals 337
14.1.7 ROSA & CO. LLC 338
14.1.7.1 Business overview 338
14.1.7.2 Products & services offered 338
14.1.8 GENEDATA AG (A DANAHER COMPANY) 339
14.1.8.1 Business overview 339
14.1.8.2 Products & services offered 340
14.1.8.3 Recent developments 341
14.1.8.3.1 Product launches & enhancements 341
14.1.8.3.2 Deals 341
14.1.9 PHYSIOMICS PLC 342
14.1.9.1 Business overview 342
14.1.9.2 Products & services offered 343
14.1.9.3 Recent developments 344
14.1.9.3.1 Deals 344
14.1.10 IN SILICO BIOSCIENCES 345
14.1.10.1 Business overview 345
14.1.10.2 Products & services offered 345
14.1.11 ALLUCENT 346
14.1.11.1 Business overview 346
14.1.11.2 Products & services offered 346
14.1.11.3 Recent developments 347
14.1.11.3.1 Deals 347
14.1.11.3.2 Expansions 347
14.1.12 OPENEYE, CADENCE MOLECULAR SCIENCES 348
14.1.12.1 Business overview 348
14.1.12.2 Products & services offered 349
14.1.12.3 Recent developments 350
14.1.12.3.1 Product enhancements 350
14.1.12.3.2 Deals 350
14.1.12.3.3 Expansions 351
14.1.13 CELLWORKS GROUP, INC. 352
14.1.13.1 Business overview 352
14.1.13.2 Products & services offered 352
14.1.13.3 Recent developments 353
14.1.13.3.1 Expansions 353
14.1.14 VERISIM LIFE 354
14.1.14.1 Business overview 354
14.1.14.2 Products & services offered 354
14.1.14.3 Recent developments 355
14.1.14.3.1 Deals 355
14.1.14.3.2 Other developments 355
14.1.15 NETABOLICS 356
14.1.15.1 Business overview 356
14.1.15.2 Products & services offered 356
14.1.16 CHARNWOOD DISCOVERY 357
14.1.16.1 Business overview 357
14.1.16.2 Products & services offered 357
14.1.16.3 Recent developments 358
14.1.16.3.1 Deals 358
14.1.17 THE MATHWORKS, INC. 359
14.1.17.1 Business overview 359
14.1.17.2 Products & services offered 359
14.1.17.3 Recent developments 360
14.1.17.3.1 Product enhancements 360
14.1.18 ANSYS, INC. 361
14.1.18.1 Business overview 361
14.1.18.2 Products & services offered 362
14.2 START-UP/SME PLAYERS 363
14.2.1 INSTEM GROUP OF COMPANIES 363
14.2.2 INSILICO MEDICINE 364
14.2.3 SCM – SOFTWARE CHEMISTRY & MATERIALS 365
14.2.4 BIOSYMETRICS, INC. 365
14.2.5 ATOMWISE INC. 366
14.2.6 INSITRO 366
14.2.7 CLINITHINK 367
15 APPENDIX 368
15.1 DISCUSSION GUIDE 368
15.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 374
15.3 CUSTOMIZATION OPTIONS 376
15.4 RELATED REPORTS 376
15.5 AUTHOR DETAILS 377
LIST OF TABLES
TABLE 1 BIOSIMULATION MARKET: ROLE OF COMPANIES IN ECOSYSTEM 70
TABLE 2 BIOSIMULATION MARKET: PORTER’S FIVE FORCES 74
TABLE 3 NORTH AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 78
TABLE 4 EUROPE: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 79
TABLE 5 ASIA PACIFIC: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 79
TABLE 6 LATIN AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 80
TABLE 7 MIDDLE EAST & AFRICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 80
TABLE 8 INDICATIVE PRICING ANALYSIS OF KEY PLAYERS, BY OFFERING 85
TABLE 9 BIOSIMULATION MARKET: KEY CONFERENCES AND EVENTS, 2024–2025 86
TABLE 10 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF TOP 3 END USERS (%) 87
TABLE 11 KEY BUYING CRITERIA FOR TOP 3 END USERS 87
TABLE 12 UNMET NEEDS IN BIOSIMULATION MARKET 88
TABLE 13 END-USER EXPECTATIONS IN BIOSIMULATION MARKET 89
TABLE 14 BIOSIMULATION MARKET, BY OFFERING, 2022–2029 (USD MILLION) 97
TABLE 15 BIOSIMULATION SOFTWARE MARKET, BY TYPE, 2022–2029 (USD MILLION) 98
TABLE 16 BIOSIMULATION SOFTWARE MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 98
TABLE 17 BIOSIMULATION MARKET FOR STANDALONE MODULES, BY TYPE,
2022–2029 (USD MILLION) 99
TABLE 18 BIOSIMULATION MARKET FOR STANDALONE MODULES, BY COUNTRY,
2022–2029 (USD MILLION) 100
TABLE 19 BIOSIMULATION MARKET FOR MOLECULAR MODELING & SIMULATION SOFTWARE, BY COUNTRY, 2022–2029 (USD MILLION) 101
TABLE 20 BIOSIMULATION MARKET FOR PK/PD MODELING & SIMULATION SOFTWARE,
BY COUNTRY, 2022–2029 (USD MILLION) 102
TABLE 21 BIOSIMULATION MARKET FOR PBPK MODELING & SIMULATION SOFTWARE,
BY COUNTRY, 2022–2029 (USD MILLION) 103
TABLE 22 BIOSIMULATION MARKET FOR TOXICITY PREDICTION SOFTWARE, BY COUNTRY, 2022–2029 (USD MILLION) 104
TABLE 23 BIOSIMULATION MARKET FOR CLINICAL TRIAL SIMULATION SOFTWARE,
BY COUNTRY, 2022–2029 (USD MILLION) 105
TABLE 24 BIOSIMULATION MARKET FOR OTHER BIOSIMULATION SOFTWARE, BY COUNTRY, 2022–2029 (USD MILLION) 106
TABLE 25 BIOSIMULATION MARKET FOR INTEGRATED SOFTWARE SUITES/PLATFORMS,
BY COUNTRY, 2022–2029 (USD MILLION) 107
TABLE 26 BIOSIMULATION SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION) 108
TABLE 27 BIOSIMULATION SERVICES MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 108
TABLE 28 BIOSIMULATION MARKET FOR CONSULTING & ADVISORY SERVICES, BY COUNTRY, 2022–2029 (USD MILLION) 109
TABLE 29 BIOSIMULATION MARKET FOR IMPLEMENTATION, TRAINING, AND SUPPORT SERVICES, BY COUNTRY, 2022–2029 (USD MILLION) 110
TABLE 30 BIOSIMULATION MARKET FOR DATA ANALYSIS & INTERPRETATION SERVICES,
BY COUNTRY, 2022–2029 (USD MILLION) 111
TABLE 31 BIOSIMULATION MARKET, BY APPLICATION, 2022–2029 (USD MILLION) 113
TABLE 32 BIOSIMULATION MARKET FOR DRUG DISCOVERY APPLICATIONS, BY TYPE,
2022–2029 (USD MILLION) 114
TABLE 33 BIOSIMULATION MARKET FOR DRUG DISCOVERY APPLICATIONS, BY COUNTRY, 2022–2029 (USD MILLION) 114
TABLE 34 BIOSIMULATION MARKET FOR TARGET IDENTIFICATION & VALIDATION,
BY COUNTRY, 2022–2029 (USD MILLION) 115
TABLE 35 BIOSIMULATION MARKET FOR LEAD IDENTIFICATION & OPTIMIZATION,
BY COUNTRY, 2022–2029 (USD MILLION) 116
TABLE 36 BIOSIMULATION MARKET FOR DRUG DEVELOPMENT APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION) 117
TABLE 37 BIOSIMULATION MARKET FOR DRUG DEVELOPMENT APPLICATIONS, BY COUNTRY, 2022–2029 (USD MILLION) 118
TABLE 38 BIOSIMULATION MARKET FOR PRECLINICAL TESTING, BY TYPE,
2022–2029 (USD MILLION) 119
TABLE 39 BIOSIMULATION MARKET FOR PRECLINICAL TESTING, BY COUNTRY,
2022–2029 (USD MILLION) 119
TABLE 40 BIOSIMULATION MARKET FOR PK/PD, BY COUNTRY, 2022–2029 (USD MILLION) 120
TABLE 41 BIOSIMULATION MARKET FOR ADME/TOXICOLOGY, BY COUNTRY,
2022–2029 (USD MILLION) 121
TABLE 42 BIOSIMULATION MARKET FOR CLINICAL TRIALS, BY TYPE,
2022–2029 (USD MILLION) 122
TABLE 43 BIOSIMULATION MARKET FOR CLINICAL TRIALS, BY COUNTRY,
2022–2029 (USD MILLION) 123
TABLE 44 BIOSIMULATION MARKET FOR PHASE I CLINICAL TRIALS, BY COUNTRY,
2022–2029 (USD MILLION) 124
TABLE 45 BIOSIMULATION MARKET FOR PHASE II CLINICAL TRIALS, BY COUNTRY,
2022–2029 (USD MILLION) 125
TABLE 46 BIOSIMULATION MARKET FOR PHASE III CLINICAL TRIALS, BY COUNTRY,
2022–2029 (USD MILLION) 126
TABLE 47 BIOSIMULATION MARKET FOR PHASE IV/POST-MARKETING SURVEILLANCE,
BY COUNTRY, 2022–2029 (USD MILLION) 127
TABLE 48 BIOSIMULATION MARKET FOR DISEASE MODELING APPLICATIONS, BY COUNTRY, 2022–2029 (USD MILLION) 128
TABLE 49 BIOSIMULATION MARKET FOR MANUFACTURING & SUPPLY CHAIN MANAGEMENT APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION) 129
TABLE 50 BIOSIMULATION MARKET FOR MANUFACTURING & SUPPLY CHAIN MANAGEMENT APPLICATIONS, BY COUNTRY, 2022–2029 (USD MILLION) 129
TABLE 51 BIOSIMULATION MARKET FOR PRODUCTION PLANNING & OPTIMIZATION,
BY COUNTRY, 2022–2029 (USD MILLION) 130
TABLE 52 BIOSIMULATION MARKET FOR QUALITY CONTROL & PROCESS MONITORING,
BY COUNTRY, 2022–2029 (USD MILLION) 131
TABLE 53 BIOSIMULATION MARKET FOR DEMAND FORECASTING & INVENTORY MANAGEMENT, BY COUNTRY, 2022–2029 (USD MILLION) 132
TABLE 54 BIOSIMULATION MARKET FOR RISK MANAGEMENT & CONTINGENCY PLANNING, BY COUNTRY, 2022–2029 (USD MILLION) 133
TABLE 55 BIOSIMULATION MARKET FOR OTHER MANUFACTURING & SUPPLY CHAIN MANAGEMENT APPLICATIONS, BY COUNTRY, 2022–2029 (USD MILLION) 134
TABLE 56 BIOSIMULATION MARKET FOR OTHER APPLICATIONS, BY COUNTRY,
2022–2029 (USD MILLION) 135
TABLE 57 BIOSIMULATION MARKET, BY THERAPEUTIC AREA, 2022–2029 (USD MILLION) 137
TABLE 58 BIOSIMULATION MARKET FOR ONCOLOGY, BY COUNTRY,
2022–2029 (USD MILLION) 138
TABLE 59 BIOSIMULATION MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY,
2022–2029 (USD MILLION) 139
TABLE 60 BIOSIMULATION MARKET FOR NEUROLOGICAL DISORDERS, BY COUNTRY,
2022–2029 (USD MILLION) 140
TABLE 61 BIOSIMULATION MARKET FOR INFECTIOUS DISEASES, BY COUNTRY,
2022–2029 (USD MILLION) 141
TABLE 62 BIOSIMULATION MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY,
2022–2029 (USD MILLION) 142
TABLE 63 BIOSIMULATION MARKET, BY REVENUE MODEL, 2022–2029 (USD MILLION) 144
TABLE 64 BIOSIMULATION MARKET FOR LICENSE-BASED MODELS, BY COUNTRY,
2022–2029 (USD MILLION) 145
TABLE 65 BIOSIMULATION MARKET FOR SUBSCRIPTION-BASED MODELS, BY COUNTRY, 2022–2029 (USD MILLION) 146
TABLE 66 BIOSIMULATION MARKET FOR SERVICE-BASED MODELS, BY COUNTRY,
2022–2029 (USD MILLION) 147
TABLE 67 BIOSIMULATION MARKET FOR PAY-PER-USE MODELS, BY COUNTRY,
2022–2029 (USD MILLION) 148
TABLE 68 BIOSIMULATION MARKET, BY DEPLOYMENT MODEL, 2022–2029 (USD MILLION) 150
TABLE 69 BIOSIMULATION MARKET FOR ON-PREMISE MODELS, BY COUNTRY,
2022–2029 (USD MILLION) 151
TABLE 70 BIOSIMULATION MARKET FOR CLOUD-BASED MODELS, BY COUNTRY,
2022–2029 (USD MILLION) 152
TABLE 71 BIOSIMULATION MARKET FOR HYBRID MODELS, BY COUNTRY,
2022–2029 (USD MILLION) 153
TABLE 72 BIOSIMULATION MARKET, BY END USER, 2022–2029 (USD MILLION) 155
TABLE 73 BIOSIMULATION MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2022–2029 (USD MILLION) 156
TABLE 74 BIOSIMULATION MARKET FOR CONTRACT RESEARCH ORGANIZATIONS,
BY COUNTRY, 2022–2029 (USD MILLION) 157
TABLE 75 BIOSIMULATION MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2022–2029 (USD MILLION) 158
TABLE 76 BIOSIMULATION MARKET FOR REGULATORY BODIES, BY COUNTRY,
2022–2029 (USD MILLION) 159
TABLE 77 BIOSIMULATION MARKET FOR OTHER END USERS, BY COUNTRY,
2022–2029 (USD MILLION) 160
TABLE 78 BIOSIMULATION MARKET, BY REGION, 2022–2029 (USD MILLION) 162
TABLE 79 NORTH AMERICA: BIOSIMULATION MARKET, BY COUNTRY,
2022–2029 (USD MILLION) 163
TABLE 80 NORTH AMERICA: BIOSIMULATION MARKET, BY OFFERING,
2022–2029 (USD MILLION) 164
TABLE 81 NORTH AMERICA: BIOSIMULATION SOFTWARE MARKET, BY TYPE,
2022–2029 (USD MILLION) 164
TABLE 82 NORTH AMERICA: BIOSIMULATION MARKET FOR STANDALONE MODULES,
BY TYPE, 2022–2029 (USD MILLION) 164
TABLE 83 NORTH AMERICA: BIOSIMULATION SERVICES MARKET, BY TYPE,
2022–2029 (USD MILLION) 165
TABLE 84 NORTH AMERICA: BIOSIMULATION MARKET, BY APPLICATION,
2022–2029 (USD MILLION) 165
TABLE 85 NORTH AMERICA: BIOSIMULATION MARKET FOR DRUG DISCOVERY APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION) 165
TABLE 86 NORTH AMERICA: BIOSIMULATION MARKET FOR DRUG DEVELOPMENT APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION) 166
TABLE 87 NORTH AMERICA: BIOSIMULATION MARKET FOR PRECLINICAL TESTING,
BY TYPE, 2022–2029 (USD MILLION) 166
TABLE 88 NORTH AMERICA: BIOSIMULATION MARKET FOR CLINICAL TRIALS, BY TYPE,
2022–2029 (USD MILLION) 166
TABLE 89 NORTH AMERICA: BIOSIMULATION MARKET FOR MANUFACTURING & SUPPLY CHAIN MANAGEMENT APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION) 167
TABLE 90 NORTH AMERICA: BIOSIMULATION MARKET, BY THERAPEUTIC AREA,
2022–2029 (USD MILLION) 167
TABLE 91 NORTH AMERICA: BIOSIMULATION MARKET, BY REVENUE MODEL,
2022–2029 (USD MILLION) 168
TABLE 92 NORTH AMERICA: BIOSIMULATION MARKET, BY DEPLOYMENT MODEL,
2022–2029 (USD MILLION) 168
TABLE 93 NORTH AMERICA: BIOSIMULATION MARKET, BY END USER,
2022–2029 (USD MILLION) 168
TABLE 94 US: BIOSIMULATION MARKET, BY OFFERING, 2022–2029 (USD MILLION) 170
TABLE 95 US: BIOSIMULATION SOFTWARE MARKET, BY TYPE, 2022–2029 (USD MILLION) 170
TABLE 96 US: BIOSIMULATION MARKET FOR STANDALONE MODULES, BY TYPE,
2022–2029 (USD MILLION) 170
TABLE 97 US: BIOSIMULATION SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION) 171
TABLE 98 US: BIOSIMULATION MARKET, BY APPLICATION, 2022–2029 (USD MILLION) 171
TABLE 99 US: BIOSIMULATION MARKET FOR DRUG DISCOVERY APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION) 171
TABLE 100 US: BIOSIMULATION MARKET FOR DRUG DEVELOPMENT APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION) 172
TABLE 101 US: BIOSIMULATION MARKET FOR PRECLINICAL TESTING, BY TYPE,
2022–2029 (USD MILLION) 172
TABLE 102 US: BIOSIMULATION MARKET FOR CLINICAL TRIALS, BY TYPE,
2022–2029 (USD MILLION) 172
TABLE 103 US: BIOSIMULATION MARKET FOR MANUFACTURING & SUPPLY CHAIN MANAGEMENT APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION) 173
TABLE 104 US: BIOSIMULATION MARKET, BY THERAPEUTIC AREA, 2022–2029 (USD MILLION) 173
TABLE 105 US: BIOSIMULATION MARKET, BY REVENUE MODEL, 2022–2029 (USD MILLION) 174
TABLE 106 US: BIOSIMULATION MARKET, BY DEPLOYMENT MODEL,
2022–2029 (USD MILLION) 174
TABLE 107 US: BIOSIMULATION MARKET, BY END USER, 2022–2029 (USD MILLION) 174
TABLE 108 CANADA: BIOSIMULATION MARKET, BY OFFERING, 2022–2029 (USD MILLION) 175
TABLE 109 CANADA: BIOSIMULATION SOFTWARE MARKET, BY TYPE,
2022–2029 (USD MILLION) 175
TABLE 110 CANADA: BIOSIMULATION MARKET FOR STANDALONE MODULES, BY TYPE,
2022–2029 (USD MILLION) 176
TABLE 111 CANADA: BIOSIMULATION SERVICES MARKET, BY TYPE,
2022–2029 (USD MILLION) 176
TABLE 112 CANADA: BIOSIMULATION MARKET, BY APPLICATION,
2022–2029 (USD MILLION) 177
TABLE 113 CANADA: BIOSIMULATION MARKET FOR DRUG DISCOVERY APPLICATIONS,
BY TYPE, 2022–2029 (USD MILLION) 177
TABLE 114 CANADA: BIOSIMULATION MARKET FOR DRUG DEVELOPMENT APPLICATIONS,
BY TYPE, 2022–2029 (USD MILLION) 177
TABLE 115 CANADA: BIOSIMULATION MARKET FOR PRECLINICAL TESTING, BY TYPE,
2022–2029 (USD MILLION) 178
TABLE 116 CANADA: BIOSIMULATION MARKET FOR CLINICAL TRIALS, BY TYPE,
2022–2029 (USD MILLION) 178
TABLE 117 CANADA: BIOSIMULATION MARKET FOR MANUFACTURING & SUPPLY CHAIN MANAGEMENT APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION) 179
TABLE 118 CANADA: BIOSIMULATION MARKET, BY THERAPEUTIC AREA,
2022–2029 (USD MILLION) 179
TABLE 119 CANADA: BIOSIMULATION MARKET, BY REVENUE MODEL,
2022–2029 (USD MILLION) 180
TABLE 120 CANADA: BIOSIMULATION MARKET, BY DEPLOYMENT MODEL,
2022–2029 (USD MILLION) 180
TABLE 121 CANADA: BIOSIMULATION MARKET, BY END USER, 2022–2029 (USD MILLION) 180
TABLE 122 EUROPE: BIOSIMULATION MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 181
TABLE 123 EUROPE: BIOSIMULATION MARKET, BY OFFERING, 2022–2029 (USD MILLION) 181
TABLE 124 EUROPE: BIOSIMULATION SOFTWARE MARKET, BY TYPE,
2022–2029 (USD MILLION) 182
TABLE 125 EUROPE: BIOSIMULATION MARKET FOR STANDALONE MODULES, BY TYPE,
2022–2029 (USD MILLION) 182
TABLE 126 EUROPE: BIOSIMULATION SERVICES MARKET, BY TYPE,
2022–2029 (USD MILLION) 183
TABLE 127 EUROPE: BIOSIMULATION MARKET, BY APPLICATION, 2022–2029 (USD MILLION) 183
TABLE 128 EUROPE: BIOSIMULATION MARKET FOR DRUG DISCOVERY APPLICATIONS,
BY TYPE, 2022–2029 (USD MILLION) 183
TABLE 129 EUROPE: BIOSIMULATION MARKET FOR DRUG DEVELOPMENT APPLICATIONS,
BY TYPE, 2022–2029 (USD MILLION) 184
TABLE 130 EUROPE: BIOSIMULATION MARKET FOR PRECLINICAL TESTING, BY TYPE,
2022–2029 (USD MILLION) 184
TABLE 131 EUROPE: BIOSIMULATION MARKET FOR CLINICAL TRIALS, BY TYPE,
2022–2029 (USD MILLION) 184
TABLE 132 EUROPE: BIOSIMULATION MARKET FOR MANUFACTURING & SUPPLY CHAIN MANAGEMENT APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION) 185
TABLE 133 EUROPE: BIOSIMULATION MARKET, BY THERAPEUTIC AREA,
2022–2029 (USD MILLION) 185
TABLE 134 EUROPE: BIOSIMULATION MARKET, BY REVENUE MODEL,
2022–2029 (USD MILLION) 186
TABLE 135 EUROPE: BIOSIMULATION MARKET, BY DEPLOYMENT MODEL,
2022–2029 (USD MILLION) 186
TABLE 136 EUROPE: BIOSIMULATION MARKET, BY END USER, 2022–2029 (USD MILLION) 186
TABLE 137 GERMANY: BIOSIMULATION MARKET, BY OFFERING, 2022–2029 (USD MILLION) 188
TABLE 138 GERMANY: BIOSIMULATION SOFTWARE MARKET, BY TYPE,
2022–2029 (USD MILLION) 188
TABLE 139 GERMANY: BIOSIMULATION MARKET FOR STANDALONE MODULES, BY TYPE, 2022–2029 (USD MILLION) 188
TABLE 140 GERMANY: BIOSIMULATION SERVICES MARKET, BY TYPE,
2022–2029 (USD MILLION) 189
TABLE 141 GERMANY: BIOSIMULATION MARKET, BY APPLICATION,
2022–2029 (USD MILLION) 189
TABLE 142 GERMANY: BIOSIMULATION MARKET FOR DRUG DISCOVERY APPLICATIONS,
BY TYPE, 2022–2029 (USD MILLION) 189
TABLE 143 GERMANY: BIOSIMULATION MARKET FOR DRUG DEVELOPMENT APPLICATIONS,
BY TYPE, 2022–2029 (USD MILLION) 190
TABLE 144 GERMANY: BIOSIMULATION MARKET FOR PRECLINICAL TESTING, BY TYPE,
2022–2029 (USD MILLION) 190
TABLE 145 GERMANY: BIOSIMULATION MARKET FOR CLINICAL TRIALS, BY TYPE,
2022–2029 (USD MILLION) 190
TABLE 146 GERMANY: BIOSIMULATION MARKET FOR MANUFACTURING & SUPPLY CHAIN MANAGEMENT APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION) 191
TABLE 147 GERMANY: BIOSIMULATION MARKET, BY THERAPEUTIC AREA,
2022–2029 (USD MILLION) 191
TABLE 148 GERMANY: BIOSIMULATION MARKET, BY REVENUE MODEL,
2022–2029 (USD MILLION) 192
TABLE 149 GERMANY: BIOSIMULATION MARKET, BY DEPLOYMENT MODEL,
2022–2029 (USD MILLION) 192
TABLE 150 GERMANY: BIOSIMULATION MARKET, BY END USER, 2022–2029 (USD MILLION) 192
TABLE 151 UK: BIOSIMULATION MARKET, BY OFFERING, 2022–2029 (USD MILLION) 193
TABLE 152 UK: BIOSIMULATION SOFTWARE MARKET, BY TYPE, 2022–2029 (USD MILLION) 193
TABLE 153 UK: BIOSIMULATION MARKET FOR STANDALONE MODULES, BY TYPE,
2022–2029 (USD MILLION) 194
TABLE 154 UK: BIOSIMULATION SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION) 194
TABLE 155 UK: BIOSIMULATION MARKET, BY APPLICATION, 2022–2029 (USD MILLION) 195
TABLE 156 UK: BIOSIMULATION MARKET FOR DRUG DISCOVERY APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION) 195
TABLE 157 UK: BIOSIMULATION MARKET FOR DRUG DEVELOPMENT APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION) 195
TABLE 158 UK: BIOSIMULATION MARKET FOR PRECLINICAL TESTING, BY TYPE,
2022–2029 (USD MILLION) 196
TABLE 159 UK: BIOSIMULATION MARKET FOR CLINICAL TRIALS, BY TYPE,
2022–2029 (USD MILLION) 196
TABLE 160 UK: BIOSIMULATION MARKET FOR MANUFACTURING & SUPPLY CHAIN MANAGEMENT APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION) 196
TABLE 161 UK: BIOSIMULATION MARKET, BY THERAPEUTIC AREA, 2022–2029 (USD MILLION) 197
TABLE 162 UK: BIOSIMULATION MARKET, BY REVENUE MODEL, 2022–2029 (USD MILLION) 197
TABLE 163 UK: BIOSIMULATION MARKET, BY DEPLOYMENT MODEL,
2022–2029 (USD MILLION) 197
TABLE 164 UK: BIOSIMULATION MARKET, BY END USER, 2022–2029 (USD MILLION) 198
TABLE 165 FRANCE: BIOSIMULATION MARKET, BY OFFERING, 2022–2029 (USD MILLION) 199
TABLE 166 FRANCE: BIOSIMULATION SOFTWARE MARKET, BY TYPE,
2022–2029 (USD MILLION) 199
TABLE 167 FRANCE: BIOSIMULATION MARKET FOR STANDALONE MODULES, BY TYPE,
2022–2029 (USD MILLION) 199
TABLE 168 FRANCE: BIOSIMULATION SERVICES MARKET, BY TYPE,
2022–2029 (USD MILLION) 200
TABLE 169 FRANCE: BIOSIMULATION MARKET, BY APPLICATION, 2022–2029 (USD MILLION) 200
TABLE 170 FRANCE: BIOSIMULATION MARKET FOR DRUG DISCOVERY APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION) 200
TABLE 171 FRANCE: BIOSIMULATION MARKET FOR DRUG DEVELOPMENT APPLICATIONS,
BY TYPE, 2022–2029 (USD MILLION) 201
TABLE 172 FRANCE: BIOSIMULATION MARKET FOR PRECLINICAL TESTING, BY TYPE,
2022–2029 (USD MILLION) 201
TABLE 173 FRANCE: BIOSIMULATION MARKET FOR CLINICAL TRIALS, BY TYPE,
2022–2029 (USD MILLION) 201
TABLE 174 FRANCE: BIOSIMULATION MARKET FOR MANUFACTURING & SUPPLY CHAIN MANAGEMENT APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION) 202
TABLE 175 FRANCE: BIOSIMULATION MARKET, BY THERAPEUTIC AREA,
2022–2029 (USD MILLION) 202
TABLE 176 FRANCE: BIOSIMULATION MARKET, BY REVENUE MODEL,
2022–2029 (USD MILLION) 203
TABLE 177 FRANCE: BIOSIMULATION MARKET, BY DEPLOYMENT MODEL,
2022–2029 (USD MILLION) 203
TABLE 178 FRANCE: BIOSIMULATION MARKET, BY END USER, 2022–2029 (USD MILLION) 203
TABLE 179 ITALY: BIOSIMULATION MARKET, BY OFFERING, 2022–2029 (USD MILLION) 204
TABLE 180 ITALY: BIOSIMULATION SOFTWARE MARKET, BY TYPE, 2022–2029 (USD MILLION) 204
TABLE 181 ITALY: BIOSIMULATION MARKET FOR STANDALONE MODULES, BY TYPE,
2022–2029 (USD MILLION) 205
TABLE 182 ITALY: BIOSIMULATION SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION) 205
TABLE 183 ITALY: BIOSIMULATION MARKET, BY APPLICATION, 2022–2029 (USD MILLION) 206
TABLE 184 ITALY: BIOSIMULATION MARKET FOR DRUG DISCOVERY APPLICATIONS,
BY TYPE, 2022–2029 (USD MILLION) 206
TABLE 185 ITALY: BIOSIMULATION MARKET FOR DRUG DEVELOPMENT APPLICATIONS,
BY TYPE, 2022–2029 (USD MILLION) 206
TABLE 186 ITALY: BIOSIMULATION MARKET FOR PRECLINICAL TESTING, BY TYPE,
2022–2029 (USD MILLION) 207
TABLE 187 ITALY: BIOSIMULATION MARKET FOR CLINICAL TRIALS, BY TYPE,
2022–2029 (USD MILLION) 207
TABLE 188 ITALY: BIOSIMULATION MARKET FOR MANUFACTURING & SUPPLY CHAIN MANAGEMENT APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION) 207
TABLE 189 ITALY: BIOSIMULATION MARKET, BY THERAPEUTIC AREA,
2022–2029 (USD MILLION) 208
TABLE 190 ITALY: BIOSIMULATION MARKET, BY REVENUE MODEL, 2022–2029 (USD MILLION) 208
TABLE 191 ITALY: BIOSIMULATION MARKET, BY DEPLOYMENT MODEL,
2022–2029 (USD MILLION) 208
TABLE 192 ITALY: BIOSIMULATION MARKET, BY END USER, 2022–2029 (USD MILLION) 209
TABLE 193 SPAIN: BIOSIMULATION MARKET, BY OFFERING, 2022–2029 (USD MILLION) 210
TABLE 194 SPAIN: BIOSIMULATION SOFTWARE MARKET, BY TYPE, 2022–2029 (USD MILLION) 210
TABLE 195 SPAIN: BIOSIMULATION MARKET FOR STANDALONE MODULES, BY TYPE,
2022–2029 (USD MILLION) 210
TABLE 196 SPAIN: BIOSIMULATION SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION) 211
TABLE 197 SPAIN: BIOSIMULATION MARKET, BY APPLICATION, 2022–2029 (USD MILLION) 211
TABLE 198 SPAIN: BIOSIMULATION MARKET FOR DRUG DISCOVERY APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION) 211
TABLE 199 SPAIN: BIOSIMULATION MARKET FOR DRUG DEVELOPMENT APPLICATIONS,
BY TYPE, 2022–2029 (USD MILLION) 212
TABLE 200 SPAIN: BIOSIMULATION MARKET FOR PRECLINICAL TESTING, BY TYPE,
2022–2029 (USD MILLION) 212
TABLE 201 SPAIN: BIOSIMULATION MARKET FOR CLINICAL TRIALS, BY TYPE,
2022–2029 (USD MILLION) 212
TABLE 202 SPAIN: BIOSIMULATION MARKET FOR MANUFACTURING & SUPPLY CHAIN MANAGEMENT APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION) 213
TABLE 203 SPAIN: BIOSIMULATION MARKET, BY THERAPEUTIC AREA,
2022–2029 (USD MILLION) 213
TABLE 204 SPAIN: BIOSIMULATION MARKET, BY REVENUE MODEL,
2022–2029 (USD MILLION) 214
TABLE 205 SPAIN: BIOSIMULATION MARKET, BY DEPLOYMENT MODEL,
2022–2029 (USD MILLION) 214
TABLE 206 SPAIN: BIOSIMULATION MARKET, BY END USER, 2022–2029 (USD MILLION) 214
TABLE 207 REST OF EUROPE: BIOSIMULATION MARKET, BY OFFERING,
2022–2029 (USD MILLION) 215
TABLE 208 REST OF EUROPE: BIOSIMULATION SOFTWARE MARKET, BY TYPE,
2022–2029 (USD MILLION) 215
TABLE 209 REST OF EUROPE: BIOSIMULATION MARKET FOR STANDALONE MODULES,
BY TYPE, 2022–2029 (USD MILLION) 216
TABLE 210 REST OF EUROPE: BIOSIMULATION SERVICES MARKET, BY TYPE,
2022–2029 (USD MILLION) 216
TABLE 211 REST OF EUROPE: BIOSIMULATION MARKET, BY APPLICATION,
2022–2029 (USD MILLION) 217
TABLE 212 REST OF EUROPE: BIOSIMULATION MARKET FOR DRUG DISCOVERY APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION) 217
TABLE 213 REST OF EUROPE: BIOSIMULATION MARKET FOR DRUG DEVELOPMENT APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION) 217
TABLE 214 REST OF EUROPE: BIOSIMULATION MARKET FOR PRECLINICAL TESTING, BY TYPE, 2022–2029 (USD MILLION) 218
TABLE 215 REST OF EUROPE: BIOSIMULATION MARKET FOR CLINICAL TRIALS, BY TYPE, 2022–2029 (USD MILLION) 218
TABLE 216 REST OF EUROPE: BIOSIMULATION MARKET FOR MANUFACTURING & SUPPLY CHAIN MANAGEMENT APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION) 218
TABLE 217 REST OF EUROPE: BIOSIMULATION MARKET, BY THERAPEUTIC AREA,
2022–2029 (USD MILLION) 219
TABLE 218 REST OF EUROPE: BIOSIMULATION MARKET, BY REVENUE MODEL,
2022–2029 (USD MILLION) 219
TABLE 219 REST OF EUROPE: BIOSIMULATION MARKET, BY DEPLOYMENT MODEL,
2022–2029 (USD MILLION) 219
TABLE 220 REST OF EUROPE: BIOSIMULATION MARKET, BY END USER,
2022–2029 (USD MILLION) 220
TABLE 221 ASIA PACIFIC: BIOSIMULATION MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 222
TABLE 222 ASIA PACIFIC: BIOSIMULATION MARKET, BY OFFERING, 2022–2029 (USD MILLION) 222
TABLE 223 ASIA PACIFIC: BIOSIMULATION SOFTWARE MARKET, BY TYPE,
2022–2029 (USD MILLION) 222
TABLE 224 ASIA PACIFIC: BIOSIMULATION MARKET FOR STANDALONE MODULES, BY TYPE, 2022–2029 (USD MILLION) 223
TABLE 225 ASIA PACIFIC: BIOSIMULATION SERVICES MARKET, BY TYPE,
2022–2029 (USD MILLION) 223
TABLE 226 ASIA PACIFIC: BIOSIMULATION MARKET, BY APPLICATION,
2022–2029 (USD MILLION) 223
TABLE 227 ASIA PACIFIC: BIOSIMULATION MARKET FOR DRUG DISCOVERY APPLICATIONS,
BY TYPE, 2022–2029 (USD MILLION) 224
TABLE 228 ASIA PACIFIC: BIOSIMULATION MARKET FOR DRUG DEVELOPMENT APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION) 224
TABLE 229 ASIA PACIFIC: BIOSIMULATION MARKET FOR PRECLINICAL TESTING, BY TYPE, 2022–2029 (USD MILLION) 224
TABLE 230 ASIA PACIFIC: BIOSIMULATION MARKET FOR CLINICAL TRIALS, BY TYPE,
2022–2029 (USD MILLION) 225
TABLE 231 ASIA PACIFIC: BIOSIMULATION MARKET FOR MANUFACTURING & SUPPLY CHAIN MANAGEMENT APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION) 225
TABLE 232 ASIA PACIFIC: BIOSIMULATION MARKET, BY THERAPEUTIC AREA,
2022–2029 (USD MILLION) 226
TABLE 233 ASIA PACIFIC: BIOSIMULATION MARKET, BY REVENUE MODEL,
2022–2029 (USD MILLION) 226
TABLE 234 ASIA PACIFIC: BIOSIMULATION MARKET, BY DEPLOYMENT MODEL,
2022–2029 (USD MILLION) 226
TABLE 235 ASIA PACIFIC: BIOSIMULATION MARKET, BY END USER,
2022–2029 (USD MILLION) 227
TABLE 236 CHINA: BIOSIMULATION MARKET, BY OFFERING, 2022–2029 (USD MILLION) 228
TABLE 237 CHINA: BIOSIMULATION SOFTWARE MARKET, BY TYPE, 2022–2029 (USD MILLION) 228
TABLE 238 CHINA: BIOSIMULATION MARKET FOR STANDALONE MODULES, BY TYPE,
2022–2029 (USD MILLION) 229
TABLE 239 CHINA: BIOSIMULATION SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION) 229
TABLE 240 CHINA: BIOSIMULATION MARKET, BY APPLICATION, 2022–2029 (USD MILLION) 229
TABLE 241 CHINA: BIOSIMULATION MARKET FOR DRUG DISCOVERY APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION) 230
TABLE 242 CHINA: BIOSIMULATION MARKET FOR DRUG DEVELOPMENT APPLICATIONS,
BY TYPE, 2022–2029 (USD MILLION) 230
TABLE 243 CHINA: BIOSIMULATION MARKET FOR PRECLINICAL TESTING, BY TYPE,
2022–2029 (USD MILLION) 230
TABLE 244 CHINA: BIOSIMULATION MARKET FOR CLINICAL TRIALS, BY TYPE,
2022–2029 (USD MILLION) 231
TABLE 245 CHINA: BIOSIMULATION MARKET FOR MANUFACTURING & SUPPLY CHAIN MANAGEMENT APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION) 231
TABLE 246 CHINA: BIOSIMULATION MARKET, BY THERAPEUTIC AREA,
2022–2029 (USD MILLION) 232
TABLE 247 CHINA: BIOSIMULATION MARKET, BY REVENUE MODEL,
2022–2029 (USD MILLION) 232
TABLE 248 CHINA: BIOSIMULATION MARKET, BY DEPLOYMENT MODEL,
2022–2029 (USD MILLION) 232
TABLE 249 CHINA: BIOSIMULATION MARKET, BY END USER, 2022–2029 (USD MILLION) 233
TABLE 250 INDIA: BIOSIMULATION MARKET, BY OFFERING, 2022–2029 (USD MILLION) 234
TABLE 251 INDIA: BIOSIMULATION SOFTWARE MARKET, BY TYPE, 2022–2029 (USD MILLION) 234
TABLE 252 INDIA: BIOSIMULATION MARKET FOR STANDALONE MODULES, BY TYPE,
2022–2029 (USD MILLION) 234
TABLE 253 INDIA: BIOSIMULATION SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION) 235
TABLE 254 INDIA: BIOSIMULATION MARKET, BY APPLICATION, 2022–2029 (USD MILLION) 235
TABLE 255 INDIA: BIOSIMULATION MARKET FOR DRUG DISCOVERY APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION) 235
TABLE 256 INDIA: BIOSIMULATION MARKET FOR DRUG DEVELOPMENT APPLICATIONS,
BY TYPE, 2022–2029 (USD MILLION) 236
TABLE 257 INDIA: BIOSIMULATION MARKET FOR PRECLINICAL TESTING, BY TYPE,
2022–2029 (USD MILLION) 236
TABLE 258 INDIA: BIOSIMULATION MARKET FOR CLINICAL TRIALS, BY TYPE,
2022–2029 (USD MILLION) 236
TABLE 259 INDIA: BIOSIMULATION MARKET FOR MANUFACTURING & SUPPLY CHAIN MANAGEMENT APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION) 237
TABLE 260 INDIA: BIOSIMULATION MARKET, BY THERAPEUTIC AREA,
2022–2029 (USD MILLION) 237
TABLE 261 INDIA: BIOSIMULATION MARKET, BY REVENUE MODEL, 2022–2029 (USD MILLION) 238
TABLE 262 INDIA: BIOSIMULATION MARKET, BY DEPLOYMENT MODEL,
2022–2029 (USD MILLION) 238
TABLE 263 INDIA: BIOSIMULATION MARKET, BY END USER, 2022–2029 (USD MILLION) 238
TABLE 264 JAPAN: BIOSIMULATION MARKET, BY OFFERING, 2022–2029 (USD MILLION) 239
TABLE 265 JAPAN: BIOSIMULATION SOFTWARE MARKET, BY TYPE, 2022–2029 (USD MILLION) 239
TABLE 266 JAPAN: BIOSIMULATION MARKET FOR STANDALONE MODULES, BY TYPE,
2022–2029 (USD MILLION) 240
TABLE 267 JAPAN: BIOSIMULATION SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION) 240
TABLE 268 JAPAN: BIOSIMULATION MARKET, BY APPLICATION, 2022–2029 (USD MILLION) 240
TABLE 269 JAPAN: BIOSIMULATION MARKET FOR DRUG DISCOVERY APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION) 241
TABLE 270 JAPAN: BIOSIMULATION MARKET FOR DRUG DEVELOPMENT APPLICATIONS,
BY TYPE, 2022–2029 (USD MILLION) 241
TABLE 271 JAPAN: BIOSIMULATION MARKET FOR PRECLINICAL TESTING, BY TYPE,
2022–2029 (USD MILLION) 241
TABLE 272 JAPAN: BIOSIMULATION MARKET FOR CLINICAL TRIALS, BY TYPE,
2022–2029 (USD MILLION) 242
TABLE 273 JAPAN: BIOSIMULATION MARKET FOR MANUFACTURING & SUPPLY CHAIN MANAGEMENT APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION) 242
TABLE 274 JAPAN: BIOSIMULATION MARKET, BY THERAPEUTIC AREA,
2022–2029 (USD MILLION) 243
TABLE 275 JAPAN: BIOSIMULATION MARKET, BY REVENUE MODEL,
2022–2029 (USD MILLION) 243
TABLE 276 JAPAN: BIOSIMULATION MARKET, BY DEPLOYMENT MODEL,
2022–2029 (USD MILLION) 243
TABLE 277 JAPAN: BIOSIMULATION MARKET, BY END USER, 2022–2029 (USD MILLION) 244
TABLE 278 REST OF ASIA PACIFIC: BIOSIMULATION MARKET, BY OFFERING,
2022–2029 (USD MILLION) 244
TABLE 279 REST OF ASIA PACIFIC: BIOSIMULATION SOFTWARE MARKET, BY TYPE,
2022–2029 (USD MILLION) 245
TABLE 280 REST OF ASIA PACIFIC: BIOSIMULATION MARKET FOR STANDALONE MODULES,
BY TYPE, 2022–2029 (USD MILLION) 245
TABLE 281 REST OF ASIA PACIFIC: BIOSIMULATION SERVICES MARKET, BY TYPE,
2022–2029 (USD MILLION) 245
TABLE 282 REST OF ASIA PACIFIC: BIOSIMULATION MARKET, BY APPLICATION,
2022–2029 (USD MILLION) 246
TABLE 283 REST OF ASIA PACIFIC: BIOSIMULATION MARKET FOR DRUG DISCOVERY APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION) 246
TABLE 284 REST OF ASIA PACIFIC: BIOSIMULATION MARKET FOR DRUG DEVELOPMENT APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION) 246
TABLE 285 REST OF ASIA PACIFIC: BIOSIMULATION MARKET FOR PRECLINICAL TESTING,
BY TYPE, 2022–2029 (USD MILLION) 247
TABLE 286 REST OF ASIA PACIFIC: BIOSIMULATION MARKET FOR CLINICAL TRIALS, BY TYPE, 2022–2029 (USD MILLION) 247
TABLE 287 REST OF ASIA PACIFIC: BIOSIMULATION MARKET FOR MANUFACTURING & SUPPLY CHAIN MANAGEMENT APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION) 247
TABLE 288 REST OF ASIA PACIFIC: BIOSIMULATION MARKET, BY THERAPEUTIC AREA,
2022–2029 (USD MILLION) 248
TABLE 289 REST OF ASIA PACIFIC: BIOSIMULATION MARKET, BY REVENUE MODEL,
2022–2029 (USD MILLION) 248
TABLE 290 REST OF ASIA PACIFIC: BIOSIMULATION MARKET, BY DEPLOYMENT MODEL,
2022–2029 (USD MILLION) 248
TABLE 291 REST OF ASIA PACIFIC: BIOSIMULATION MARKET, BY END USER,
2022–2029 (USD MILLION) 249
TABLE 292 LATIN AMERICA: BIOSIMULATION MARKET, BY COUNTRY,
2022–2029 (USD MILLION) 249
TABLE 293 LATIN AMERICA: BIOSIMULATION MARKET, BY OFFERING,
2022–2029 (USD MILLION) 250
TABLE 294 LATIN AMERICA: BIOSIMULATION SOFTWARE MARKET, BY TYPE,
2022–2029 (USD MILLION) 250
TABLE 295 LATIN AMERICA: BIOSIMULATION MARKET FOR STANDALONE MODULES, BY TYPE, 2022–2029 (USD MILLION) 250
TABLE 296 LATIN AMERICA: BIOSIMULATION SERVICES MARKET, BY TYPE,
2022–2029 (USD MILLION) 251
TABLE 297 LATIN AMERICA: BIOSIMULATION MARKET, BY APPLICATION,
2022–2029 (USD MILLION) 251
TABLE 298 LATIN AMERICA: BIOSIMULATION MARKET FOR DRUG DISCOVERY APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION) 251
TABLE 299 LATIN AMERICA: BIOSIMULATION MARKET FOR DRUG DEVELOPMENT APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION) 252
TABLE 300 LATIN AMERICA: BIOSIMULATION MARKET FOR PRECLINICAL TESTING,
BY TYPE, 2022–2029 (USD MILLION) 252
TABLE 301 LATIN AMERICA: BIOSIMULATION MARKET FOR CLINICAL TRIALS, BY TYPE,
2022–2029 (USD MILLION) 252
TABLE 302 LATIN AMERICA: BIOSIMULATION MARKET FOR MANUFACTURING & SUPPLY CHAIN MANAGEMENT APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION) 253
TABLE 303 LATIN AMERICA: BIOSIMULATION MARKET, BY THERAPEUTIC AREA,
2022–2029 (USD MILLION) 253
TABLE 304 LATIN AMERICA: BIOSIMULATION MARKET, BY REVENUE MODEL,
2022–2029 (USD MILLION) 254
TABLE 305 LATIN AMERICA: BIOSIMULATION MARKET, BY DEPLOYMENT MODEL,
2022–2029 (USD MILLION) 254
TABLE 306 LATIN AMERICA: BIOSIMULATION MARKET, BY END USER,
2022–2029 (USD MILLION) 254
TABLE 307 BRAZIL: BIOSIMULATION MARKET, BY OFFERING, 2022–2029 (USD MILLION) 255
TABLE 308 BRAZIL: BIOSIMULATION SOFTWARE MARKET, BY TYPE,
2022–2029 (USD MILLION) 256
TABLE 309 BRAZIL: BIOSIMULATION MARKET FOR STANDALONE MODULES, BY TYPE,
2022–2029 (USD MILLION) 256
TABLE 310 BRAZIL: BIOSIMULATION SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION) 256
TABLE 311 BRAZIL: BIOSIMULATION MARKET, BY APPLICATION, 2022–2029 (USD MILLION) 257
TABLE 312 BRAZIL: BIOSIMULATION MARKET FOR DRUG DISCOVERY APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION) 257
TABLE 313 BRAZIL: BIOSIMULATION MARKET FOR DRUG DEVELOPMENT APPLICATIONS,
BY TYPE, 2022–2029 (USD MILLION) 257
TABLE 314 BRAZIL: BIOSIMULATION MARKET FOR PRECLINICAL TESTING, BY TYPE,
2022–2029 (USD MILLION) 258
TABLE 315 BRAZIL: BIOSIMULATION MARKET FOR CLINICAL TRIALS, BY TYPE,
2022–2029 (USD MILLION) 258
TABLE 316 BRAZIL: BIOSIMULATION MARKET FOR MANUFACTURING & SUPPLY CHAIN MANAGEMENT APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION) 258
TABLE 317 BRAZIL: BIOSIMULATION MARKET, BY THERAPEUTIC AREA,
2022–2029 (USD MILLION) 259
TABLE 318 BRAZIL: BIOSIMULATION MARKET, BY REVENUE MODEL,
2022–2029 (USD MILLION) 259
TABLE 319 BRAZIL: BIOSIMULATION MARKET, BY DEPLOYMENT MODEL,
2022–2029 (USD MILLION) 259
TABLE 320 BRAZIL: BIOSIMULATION MARKET, BY END USER, 2022–2029 (USD MILLION) 260
TABLE 321 MEXICO: BIOSIMULATION MARKET, BY OFFERING, 2022–2029 (USD MILLION) 260
TABLE 322 MEXICO: BIOSIMULATION SOFTWARE MARKET, BY TYPE, 2022–2029 (USD MILLION) 261
TABLE 323 MEXICO: BIOSIMULATION MARKET FOR STANDALONE MODULES, BY TYPE, 2022–2029 (USD MILLION) 261
TABLE 324 MEXICO: BIOSIMULATION SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION) 261
TABLE 325 MEXICO: BIOSIMULATION MARKET, BY APPLICATION, 2022–2029 (USD MILLION) 262
TABLE 326 MEXICO: BIOSIMULATION MARKET FOR DRUG DISCOVERY APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION) 262
TABLE 327 MEXICO: BIOSIMULATION MARKET FOR DRUG DEVELOPMENT APPLICATIONS,
BY TYPE, 2022–2029 (USD MILLION) 262
TABLE 328 MEXICO: BIOSIMULATION MARKET FOR PRECLINICAL TESTING, BY TYPE,
2022–2029 (USD MILLION) 263
TABLE 329 MEXICO: BIOSIMULATION MARKET FOR CLINICAL TRIALS, BY TYPE,
2022–2029 (USD MILLION) 263
TABLE 330 MEXICO: BIOSIMULATION MARKET FOR MANUFACTURING & SUPPLY CHAIN MANAGEMENT APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION) 263
TABLE 331 MEXICO: BIOSIMULATION MARKET, BY THERAPEUTIC AREA,
2022–2029 (USD MILLION) 264
TABLE 332 MEXICO: BIOSIMULATION MARKET, BY REVENUE MODEL,
2022–2029 (USD MILLION) 264
TABLE 333 MEXICO: BIOSIMULATION MARKET, BY DEPLOYMENT MODEL,
2022–2029 (USD MILLION) 264
TABLE 334 MEXICO: BIOSIMULATION MARKET, BY END USER, 2022–2029 (USD MILLION) 265
TABLE 335 REST OF LATIN AMERICA: BIOSIMULATION MARKET, BY OFFERING,
2022–2029 (USD MILLION) 265
TABLE 336 REST OF LATIN AMERICA: BIOSIMULATION SOFTWARE MARKET, BY TYPE,
2022–2029 (USD MILLION) 266
TABLE 337 REST OF LATIN AMERICA: BIOSIMULATION MARKET FOR STANDALONE MODULES, BY TYPE, 2022–2029 (USD MILLION) 266
TABLE 338 REST OF LATIN AMERICA: BIOSIMULATION SERVICES MARKET, BY TYPE,
2022–2029 (USD MILLION) 266
TABLE 339 REST OF LATIN AMERICA: BIOSIMULATION MARKET, BY APPLICATION,
2022–2029 (USD MILLION) 267
TABLE 340 REST OF LATIN AMERICA: BIOSIMULATION MARKET FOR DRUG DISCOVERY APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION) 267
TABLE 341 REST OF LATIN AMERICA: BIOSIMULATION MARKET FOR DRUG DEVELOPMENT APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION) 267
TABLE 342 REST OF LATIN AMERICA: BIOSIMULATION MARKET FOR PRECLINICAL TESTING,
BY TYPE, 2022–2029 (USD MILLION) 268
TABLE 343 REST OF LATIN AMERICA: BIOSIMULATION MARKET FOR CLINICAL TRIALS, BY TYPE, 2022–2029 (USD MILLION) 268
TABLE 344 REST OF LATIN AMERICA: BIOSIMULATION MARKET FOR MANUFACTURING & SUPPLY CHAIN MANAGEMENT APPLICATIONS, BY TYPE,
2022–2029 (USD MILLION) 268
TABLE 345 REST OF LATIN AMERICA: BIOSIMULATION MARKET, BY THERAPEUTIC AREA, 2022–2029 (USD MILLION) 269
TABLE 346 REST OF LATIN AMERICA: BIOSIMULATION MARKET, BY REVENUE MODEL,
2022–2029 (USD MILLION) 269
TABLE 347 REST OF LATIN AMERICA: BIOSIMULATION MARKET, BY DEPLOYMENT MODEL, 2022–2029 (USD MILLION) 269
TABLE 348 REST OF LATIN AMERICA: BIOSIMULATION MARKET, BY END USER,
2022–2029 (USD MILLION) 270
TABLE 349 MIDDLE EAST & AFRICA: BIOSIMULATION MARKET, BY COUNTRY,
2022–2029 (USD MILLION) 271
TABLE 350 MIDDLE EAST & AFRICA: BIOSIMULATION MARKET, BY OFFERING,
2022–2029 (USD MILLION) 271
TABLE 351 MIDDLE EAST & AFRICA: BIOSIMULATION SOFTWARE MARKET, BY TYPE,
2022–2029 (USD MILLION) 271
TABLE 352 MIDDLE EAST & AFRICA: BIOSIMULATION MARKET FOR STANDALONE MODULES, BY TYPE, 2022–2029 (USD MILLION) 272
TABLE 353 MIDDLE EAST & AFRICA: BIOSIMULATION SERVICES MARKET, BY TYPE,
2022–2029 (USD MILLION) 272
TABLE 354 MIDDLE EAST & AFRICA: BIOSIMULATION MARKET, BY APPLICATION,
2022–2029 (USD MILLION) 273
TABLE 355 MIDDLE EAST & AFRICA: BIOSIMULATION MARKET FOR DRUG DISCOVERY APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION) 273
TABLE 356 MIDDLE EAST & AFRICA: BIOSIMULATION MARKET FOR DRUG DEVELOPMENT APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION) 273
TABLE 357 MIDDLE EAST & AFRICA: BIOSIMULATION MARKET FOR PRECLINICAL TESTING,
BY TYPE, 2022–2029 (USD MILLION) 274
TABLE 358 MIDDLE EAST & AFRICA: BIOSIMULATION MARKET FOR CLINICAL TRIALS, BY TYPE, 2022–2029 (USD MILLION) 274
TABLE 359 MIDDLE EAST & AFRICA: BIOSIMULATION MARKET FOR MANUFACTURING & SUPPLY CHAIN MANAGEMENT APPLICATIONS, BY TYPE,
2022–2029 (USD MILLION) 274
TABLE 360 MIDDLE EAST & AFRICA: BIOSIMULATION MARKET, BY THERAPEUTIC AREA,
2022–2029 (USD MILLION) 275
TABLE 361 MIDDLE EAST & AFRICA: BIOSIMULATION MARKET, BY REVENUE MODEL,
2022–2029 (USD MILLION) 275
TABLE 362 MIDDLE EAST & AFRICA: BIOSIMULATION MARKET, BY DEPLOYMENT MODEL, 2022–2029 (USD MILLION) 275
TABLE 363 MIDDLE EAST & AFRICA: BIOSIMULATION MARKET, BY END USER,
2022–2029 (USD MILLION) 276
TABLE 364 GCC COUNTRIES: BIOSIMULATION MARKET, BY OFFERING,
2022–2029 (USD MILLION) 277
TABLE 365 GCC COUNTRIES: BIOSIMULATION SOFTWARE MARKET, BY TYPE,
2022–2029 (USD MILLION) 277
TABLE 366 GCC COUNTRIES: BIOSIMULATION MARKET FOR STANDALONE MODULES, BY TYPE, 2022–2029 (USD MILLION) 278
TABLE 367 GCC COUNTRIES: BIOSIMULATION SERVICES MARKET, BY TYPE,
2022–2029 (USD MILLION) 278
TABLE 368 GCC COUNTRIES: BIOSIMULATION MARKET, BY APPLICATION,
2022–2029 (USD MILLION) 279
TABLE 369 GCC COUNTRIES: BIOSIMULATION MARKET FOR DRUG DISCOVERY APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION) 279
TABLE 370 GCC COUNTRIES: BIOSIMULATION MARKET FOR DRUG DEVELOPMENT APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION) 279
TABLE 371 GCC COUNTRIES: BIOSIMULATION MARKET FOR PRECLINICAL TESTING, BY TYPE, 2022–2029 (USD MILLION) 280
TABLE 372 GCC COUNTRIES: BIOSIMULATION MARKET FOR CLINICAL TRIALS, BY TYPE,
2022–2029 (USD MILLION) 280
TABLE 373 GCC COUNTRIES: BIOSIMULATION MARKET FOR MANUFACTURING & SUPPLY CHAIN MANAGEMENT APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION) 280
TABLE 374 GCC COUNTRIES: BIOSIMULATION MARKET, BY THERAPEUTIC AREA,
2022–2029 (USD MILLION) 281
TABLE 375 GCC COUNTRIES: BIOSIMULATION MARKET, BY REVENUE MODEL,
2022–2029 (USD MILLION) 281
TABLE 376 GCC COUNTRIES: BIOSIMULATION MARKET, BY DEPLOYMENT MODEL,
2022–2029 (USD MILLION) 281
TABLE 377 GCC COUNTRIES: BIOSIMULATION MARKET, BY END USER,
2022–2029 (USD MILLION) 282
TABLE 378 REST OF MIDDLE EAST & AFRICA: BIOSIMULATION MARKET, BY OFFERING,
2022–2029 (USD MILLION) 283
TABLE 379 REST OF MIDDLE EAST & AFRICA: BIOSIMULATION SOFTWARE MARKET, BY TYPE, 2022–2029 (USD MILLION) 283
TABLE 380 REST OF MIDDLE EAST & AFRICA: BIOSIMULATION MARKET FOR STANDALONE MODULES, BY TYPE, 2022–2029 (USD MILLION) 283
TABLE 381 REST OF MIDDLE EAST & AFRICA: BIOSIMULATION SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION) 284
TABLE 382 REST OF MIDDLE EAST & AFRICA: BIOSIMULATION MARKET, BY APPLICATION, 2022–2029 (USD MILLION) 284
TABLE 383 REST OF MIDDLE EAST & AFRICA: BIOSIMULATION MARKET FOR DRUG DISCOVERY APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION) 285
TABLE 384 REST OF MIDDLE EAST & AFRICA: BIOSIMULATION MARKET FOR DRUG DEVELOPMENT APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION) 285
TABLE 385 REST OF MIDDLE EAST & AFRICA: BIOSIMULATION MARKET FOR PRECLINICAL TESTING, BY TYPE, 2022–2029 (USD MILLION) 285
TABLE 386 REST OF MIDDLE EAST & AFRICA: BIOSIMULATION MARKET FOR CLINICAL TRIALS, BY TYPE, 2022–2029 (USD MILLION) 286
TABLE 387 REST OF MIDDLE EAST & AFRICA: BIOSIMULATION MARKET FOR MANUFACTURING & SUPPLY CHAIN MANAGEMENT APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION) 286
TABLE 388 REST OF MIDDLE EAST & AFRICA: BIOSIMULATION MARKET, BY THERAPEUTIC AREA, 2022–2029 (USD MILLION) 287
TABLE 389 REST OF MIDDLE EAST & AFRICA: BIOSIMULATION MARKET, BY REVENUE MODEL, 2022–2029 (USD MILLION) 287
TABLE 390 REST OF MIDDLE EAST & AFRICA NORTH AMERICA: BIOSIMULATION MARKET,
BY DEPLOYMENT MODEL, 2022–2029 (USD MILLION) 287
TABLE 391 REST OF MIDDLE EAST & AFRICA: BIOSIMULATION MARKET, BY END USER,
2022–2029 (USD MILLION) 288
TABLE 392 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN BIOSIMULATION MARKET 290
TABLE 393 BIOSIMULATION MARKET: DEGREE OF COMPETITION 292
TABLE 394 BIOSIMULATION MARKET: OFFERING FOOTPRINT 298
TABLE 395 BIOSIMULATION MARKET: APPLICATION FOOTPRINT 299
TABLE 396 BIOSIMULATION MARKET: END-USER FOOTPRINT 300
TABLE 397 BIOSIMULATION MARKET: REGION FOOTPRINT 301
TABLE 398 BIOSIMULATION MARKET: DETAILED LIST OF KEY START-UPS/SMES 304
TABLE 399 BIOSIMULATION MARKET: COMPETITIVE BENCHMARKING OF KEY EMERGING PLAYERS/STARTUPS 305
TABLE 400 BIOSIMULATION MARKET: PRODUCT LAUNCHES & ENHANCEMENTS, JANUARY 2021–OCTOBER 2024 308
TABLE 401 BIOSIMULATION MARKET: DEALS, JANUARY 2021–OCTOBER 2024 309
TABLE 402 BIOSIMULATION MARKET: EXPANSIONS, JANUARY 2021–OCTOBER 2024 310
TABLE 403 BIOSIMULATION MARKET: OTHER DEVELOPMENTS,
JANUARY 2021–OCTOBER 2024 310
TABLE 404 CERTARA, USA: COMPANY OVERVIEW 311
TABLE 405 CERTARA, USA: PRODUCTS & SERVICES OFFERED 312
TABLE 406 CERTARA, USA: PRODUCT LAUNCHES & ENHANCEMENTS, JANUARY 2021−OCTOBER 2024 314
TABLE 407 CERTARA, USA: DEALS, JANUARY 2021−OCTOBER 2024 315
TABLE 408 DASSAULT SYSTÈMES: COMPANY OVERVIEW 317
TABLE 409 DASSAULT SYSTÈMES: PRODUCTS & SERVICES OFFERED 318
TABLE 410 DASSAULT SYSTÈMES: DEALS, JANUARY 2021−JUNE 2024 319
TABLE 411 SCHRÖDINGER, INC.: COMPANY OVERVIEW 321
TABLE 412 SCHRÖDINGER, INC.: PRODUCTS & SERVICES OFFERED 322
TABLE 413 SCHRÖDINGER, INC.: DEALS, JANUARY 2021−OCTOBER 2024 324
TABLE 414 SIMULATIONS PLUS: COMPANY OVERVIEW 326
TABLE 415 SIMULATIONS PLUS: PRODUCTS & SERVICES OFFERED 327
TABLE 416 SIMULATIONS PLUS: PRODUCT LAUNCHES & ENHANCEMENTS, JANUARY 2021−OCTOBER 2024 331
TABLE 417 SIMULATIONS PLUS: DEALS, JANUARY 2021−OCTOBER 2024 332
TABLE 418 SIMULATIONS PLUS: OTHER DEVELOPMENTS, JANUARY 2021–OCTOBER 2024 333
TABLE 419 ADVANCED CHEMISTRY DEVELOPMENT, INC.: COMPANY OVERVIEW 334
TABLE 420 ADVANCED CHEMISTRY DEVELOPMENT, INC.: PRODUCTS & SERVICES OFFERED 334
TABLE 421 ADVANCED CHEMISTRY DEVELOPMENT, INC.: PRODUCT LAUNCHES & ENHANCEMENTS, JANUARY 2021−OCTOBER 2024 335
TABLE 422 ADVANCED CHEMISTRY DEVELOPMENT, INC.: DEALS,
JANUARY 2021−OCTOBER 2024 335
TABLE 423 CHEMICAL COMPUTING GROUP ULC: COMPANY OVERVIEW 336
TABLE 424 CHEMICAL COMPUTING GROUP ULC: PRODUCTS & SERVICES OFFERED 336
TABLE 425 CHEMICAL COMPUTING GROUP ULC: DEALS, JANUARY 2021−OCTOBER 2024 337
TABLE 426 ROSA & CO. LLC: COMPANY OVERVIEW 338
TABLE 427 ROSA & CO. LLC: PRODUCTS & SERVICES OFFERED 338
TABLE 428 GENEDATA AG (A DANAHER COMPANY): COMPANY OVERVIEW 339
TABLE 429 GENEDATA AG (A DANAHER COMPANY): PRODUCTS & SERVICES OFFERED 340
TABLE 430 GENEDATA AG (A DANAHER COMPANY): PRODUCT LAUNCHES & ENHANCEMENTS, JANUARY 2021−OCTOBER 2024 341
TABLE 431 GENEDATA AG (A DANAHER COMPANY): DEALS, JANUARY 2021−OCTOBER 2024 341
TABLE 432 PHYSIOMICS PLC: COMPANY OVERVIEW 342
TABLE 433 PHYSIOMICS PLC: PRODUCTS & SERVICES OFFERED 343
TABLE 434 PHYSIOMICS PLC: DEALS, JANUARY 2021−OCTOBER 2024 344
TABLE 435 IN SILICO BIOSCIENCES: COMPANY OVERVIEW 345
TABLE 436 IN SILICO BIOSCIENCES: PRODUCTS & SERVICES OFFERED 345
TABLE 437 ALLUCENT: COMPANY OVERVIEW 346
TABLE 438 ALLUCENT: PRODUCTS & SERVICES OFFERED 346
TABLE 439 ALLUCENT: DEALS, JANUARY 2021−OCTOBER 2024 347
TABLE 440 ALLUCENT: EXPANSIONS, JANUARY 2021–OCTOBER 2024 347
TABLE 441 OPENEYE, CADENCE MOLECULAR SCIENCES: COMPANY OVERVIEW 348
TABLE 442 OPENEYE, CADENCE MOLECULAR SCIENCES: PRODUCTS & SERVICES OFFERED 349
TABLE 443 OPENEYE, CADENCE MOLECULAR SCIENCES: PRODUCT ENHANCEMENTS, JANUARY 2021−OCTOBER 2024 350
TABLE 444 OPENEYE, CADENCE MOLECULAR SCIENCES: DEALS,
JANUARY 2021−OCTOBER 2024 350
TABLE 445 OPENEYE, CADENCE MOLECULAR SCIENCES: EXPANSIONS,
JANUARY 2021–OCTOBER 2024 351
TABLE 446 CELLWORKS GROUP, INC.: COMPANY OVERVIEW 352
TABLE 447 CELLWORKS GROUP, INC.: PRODUCTS & SERVICES OFFERED 352
TABLE 448 CELLWORKS GROUP, INC.: EXPANSIONS, JANUARY 2021–OCTOBER 2024 353
TABLE 449 VERISIM LIFE: COMPANY OVERVIEW 354
TABLE 450 VERISIM LIFE: PRODUCTS & SERVICES OFFERED 354
TABLE 451 VERISIM LIFE: DEALS, JANUARY 2021−OCTOBER 2024 355
TABLE 452 VERISIM LIFE: OTHER DEVELOPMENTS, JANUARY 2021–OCTOBER 2024 355
TABLE 453 NETABOLICS: COMPANY OVERVIEW 356
TABLE 454 NETABOLICS: PRODUCTS & SERVICES OFFERED 356
TABLE 455 CHARNWOOD DISCOVERY: COMPANY OVERVIEW 357
TABLE 456 CHARNWOOD DISCOVERY: PRODUCTS & SERVICES OFFERED 357
TABLE 457 CHARNWOOD DISCOVERY: DEALS, JANUARY 2021−OCTOBER 2024 358
TABLE 458 THE MATHWORKS, INC.: COMPANY OVERVIEW 359
TABLE 459 THE MATHWORKS, INC.: PRODUCTS & SERVICES OFFERED 359
TABLE 460 THE MATHWORKS, INC.: PRODUCT ENHANCEMENTS,
JANUARY 2021−OCTOBER 2024 360
TABLE 461 ANSYS, INC.: COMPANY OVERVIEW 361
TABLE 462 ANSYS, INC.: PRODUCTS & SERVICES OFFERED 362
LIST OF FIGURES
FIGURE 1 BIOSIMULATION MARKET SEGMENTATION & REGIONAL SCOPE 36
FIGURE 2 RESEARCH DESIGN 41
FIGURE 3 PRIMARY SOURCES 44
FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS (DEMAND SIDE): BY COMPANY TYPE, DESIGNATION, AND REGION 46
FIGURE 5 MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS 47
FIGURE 6 TOP-DOWN APPROACH 48
FIGURE 7 CAGR PROJECTIONS, 2024–2029 49
FIGURE 8 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS 50
FIGURE 9 DATA TRIANGULATION 51
FIGURE 10 BIOSIMULATION MARKET, BY OFFERING, 2024 VS. 2029 (USD MILLION) 54
FIGURE 11 BIOSIMULATION MARKET, BY APPLICATION, 2024 VS. 2029 (USD MILLION) 55
FIGURE 12 BIOSIMULATION MARKET, BY THERAPEUTIC AREA, 2024 VS. 2029 (USD MILLION) 55
FIGURE 13 BIOSIMULATION MARKET, BY REVENUE MODEL, 2024 VS. 2029 (USD MILLION) 56
FIGURE 14 BIOSIMULATION MARKET, BY DEPLOYMENT MODEL,
2024 VS. 2029 (USD MILLION) 57
FIGURE 15 BIOSIMULATION MARKET, BY END USER, 2024 VS. 2029 (USD MILLION) 58
FIGURE 16 GEOGRAPHIC SNAPSHOT OF BIOSIMULATION MARKET 59
FIGURE 17 INCREASING R&D EXPENDITURE ON DRUG DISCOVERY & DEVELOPMENT BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES TO DRIVE MARKET 60
FIGURE 18 CHINA DOMINATED MARKET IN ASIA PACIFIC IN 2023 61
FIGURE 19 INDIA TO REGISTER HIGHEST GROWTH RATE DURING FORECAST PERIOD 62
FIGURE 20 NORTH AMERICA TO DOMINATE BIOSIMULATION MARKET DURING FORECAST PERIOD 62
FIGURE 21 EMERGING ECONOMIES TO REGISTER HIGHER GROWTH RATES DURING FORECAST PERIOD 63
FIGURE 22 BIOSIMULATION MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 64
FIGURE 23 BIOSIMULATION MARKET: ECOSYSTEM ANALYSIS 70
FIGURE 24 BIOSIMULATION MARKET: VALUE CHAIN ANALYSIS 72
FIGURE 25 BIOSIMULATION MARKET: PORTER’S FIVE FORCES ANALYSIS 74
FIGURE 26 PATENT PUBLICATION TRENDS IN BIOSIMULATION MARKET, 2015–2024 81
FIGURE 27 BIOSIMULATION MARKET: PATENT ANALYSIS, JANUARY 2015–SEPTEMBER 2024 82
FIGURE 28 INDICATIVE PRICING ANALYSIS FOR BIOSIMULATION SOFTWARE 85
FIGURE 29 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF TOP 3 END USERS 86
FIGURE 30 KEY BUYING CRITERIA FOR TOP 3 END USERS 87
FIGURE 31 TRENDS & DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 88
FIGURE 32 BIOSIMULATION MARKET: INVESTMENT & FUNDING SCENARIO 90
FIGURE 33 MARKET POTENTIAL OF AI/GENERATIVE AI ON BIOSIMULATION 91
FIGURE 34 IMPACT OF AI/GEN AI ON INTERCONNECTED AND ADJACENT ECOSYSTEMS 92
FIGURE 35 NORTH AMERICA: BIOSIMULATION MARKET SNAPSHOT 163
FIGURE 36 ASIA PACIFIC: BIOSIMULATION MARKET SNAPSHOT 221
FIGURE 37 REVENUE ANALYSIS OF KEY PLAYERS IN BIOSIMULATION MARKET,
2019–2023 (USD BILLION) 291
FIGURE 38 BIOSIMULATION MARKET: MARKET SHARE ANALYSIS (2023) 292
FIGURE 39 RANKING OF KEY PLAYERS IN BIOSIMULATION MARKET, 2023 294
FIGURE 40 BIOSIMULATION MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2023 296
FIGURE 41 BIOSIMULATION MARKET: COMPANY FOOTPRINT 297
FIGURE 42 BIOSIMULATION MARKET: COMPANY EVALUATION MATRIX
(START-UPS/SMES), 2023 303
FIGURE 43 EV/EBITDA OF KEY VENDORS 306
FIGURE 44 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF BIOSIMULATION VENDORS 306
FIGURE 45 BIOSIMULATION MARKET: BRAND/PRODUCT COMPARATIVE ANALYSIS 307
FIGURE 46 CERTARA, USA: COMPANY SNAPSHOT (2023) 312
FIGURE 47 DASSAULT SYSTÈMES: COMPANY SNAPSHOT (2023) 317
FIGURE 48 SCHRÖDINGER, INC.: COMPANY SNAPSHOT (2023) 322
FIGURE 49 SIMULATIONS PLUS: COMPANY SNAPSHOT (2023) 327
FIGURE 50 GENEDATA AG (A DANAHER COMPANY): COMPANY SNAPSHOT (2023) 340
FIGURE 51 PHYSIOMICS PLC: COMPANY SNAPSHOT (2023) 342
FIGURE 52 OPENEYE, CADENCE MOLECULAR SCIENCES: COMPANY SNAPSHOT (2023) 349
FIGURE 53 ANSYS, INC.: COMPANY SNAPSHOT (2023) 361
MarketsandMarkets（マーケッツアンドマーケッツ）は世界中の企業に高い評価を得ており、著名メディアでの引用頻度も高い、インドの最大手級の市場調査会社です。広範な市場を対象にした市場調査レポートを出版しています。
※MarketsandMarketsの調査レポートはほぼ全タイトルご注文後、最短3時間～12時間以内（営業日基準）にご納品可能です。
ライセンス別価格表
調査会社の事情により予告なしに変更されることがございます。最新の状況およびその他のパターンについてはお問い合わせください。
ライセンスタイプ1
| シングルユーザ | マルチユーザ | コーポレート | エンタープライズサイト |
| USD4,950 | USD6,650 | USD8,150 | USD10,000 |
ライセンスタイプ2
| シングルユーザ | マルチユーザ | コーポレート | エンタープライズサイト |
| USD7,150 | USD8,500 | USD9,650 | USD11,000 |
ライセンスタイプ3
| シングルユーザ | マルチユーザ | コーポレート | エンタープライズサイト |
| USD8,150 | お問合せください | お問合せください | お問合せください |
ライセンスタイプ4
| シングルユーザ | マルチユーザ | コーポレート | エンタープライズサイト |
| USD9,000 | USD10,500 | USD12,000 | USD13,500 |
ミニレポート ※定性調査にフォーカスした調査レポートです。詳細はお問合せください。
| シングルユーザ | コーポレート |
| USD 2,650 | USD 4,250 |
ご購入に関するご案内
価格・納期について
- 価格
- ウェブサイトに記載の外貨（定価）を見積日のTTSレートで換算後消費税を加えた金額が弊社からの請求金額になります。見積金額はレート変動に関係なく見積書発行日より2週間有効です。手数料（ハンドリングチャージ）無料。
- ライセンス
- シングルユーザライセンス
- 1名のみレポートファイルのご利用が可能です。
- マルチユーザライセンス
- 同一企業内（関連会社除く）5名までレポートファイルのご利用が可能です。
- コーポレートライセンス
- 同一企業および100％持株会社間・人数無制限でレポートファイルのご利用が可能です。
- エンタープライズサイトライセンス
- 特別ライセンスです。適用範囲についてはお問合せください。
- シングルユーザライセンス
- 納品形態
- Eメール
- 納期
- 最短3時間以内にご納品可能です。通常ご注文後24時間以内（営業日基準）
ご注文方法
- レポートページ内のお問い合わせフォームより見積もりをご請求ください。確認次第見積書と発注書をお送りいたします。既に弊社の見積書をお持ちの場合にはEメールまたはFAXでご注文ください。
その他
- 商品の性質上、ご注文後のキャンセル/返品/交換はできません。ご了承ください。
株式会社SEMABIZはMarketsandMarketsの日本に拠点をおく販売代理店として、MarketsandMarketsのレポートを販売しております。サンプルページのご依頼、見積り、レポートに関するご質問など購入前のご相談はいつでもお気軽にご連絡ください。
最新調査レポート
- 自動車用アラミド繊維市場規模、シェア、動向、2030年までの世界予測 2025-12-15
- ポリヒドロキシアルカノエート (PHA) 市場規模、シェア、動向、2030年までの世界予測 2025-12-15
- 複合輸送市場規模、シェア、動向、2032年までの世界予測 2025-12-12
- 有機酸市場規模、シェア、動向、2030年までの世界予測 2025-12-11
- ハイブリッドボンディング市場規模、シェア、動向、2032年までの世界予測 2025-12-11